Press Releases

Intelerad Acquires PenRad Technologies, Inc., Expanding Breast Imaging and Lung Screening Capabilities

The new deal will secure expanded access to essential solutions that will help ensure radiologists, technologists and other healthcare professionals can drive greater productivity and meet higher oncology screening demand, while improving patient care RALEIGH, NC and MONTREAL, CANADA, August 16, 2022 – Intelerad Medical Systems™, a leading global provider of enterprise medical imaging solutions, […]

Novarad and PenRad partner to provide further diagnostic tracking functionality to healthcare providers

Healthcare IT company Novarad to offer PenRad’s PenLung automated tracking and reporting system for lung screening and lung cancer as part of its diagnostic suite SALT LAKE CITY – Novarad, a leading provider of medical software, announced today that it has expanded its strategic partnership with mammography analytics company, PenRad, Inc. PenRad’s automated tracking and […]

PenAlert: A new paradigm in diagnostic imaging reports

PENRAD™ ANNOUNCES PENALERT.  A NEW PARADIGM IN DIAGNOSTIC IMAGING REPORTS IN PATIENT'S LANGUAGE AND TERMINOLOGY. PenRad offers a solution to reduce Radiologists' liability and malpractice, without practice burden.   Buffalo, MN, July 7, 2020 As various regulations evolve and malpractice rates increase, imaging providers need to take a proactive approach to notify patients directly of [...]

PenRad Blog

Four Things Happen when Imaging Centers Utilize Digital Patient Engagement

Consumers are accustomed to using their mobile devices and digital communication for everyday activities such as buying goods, attending virtual meetings, entertainment and even ordering food.  Healthcare consumers are no different.  In a recent study by Dynex1 which surveyed 1000 adults over 18 years of age, researchers found 80% of patients prefer electronic communication with [...]

PenRad is Your Most Trusted Mammography Analytics Partner. PenRad is Your Most Trusted Business Partner.

While it is well established PenRad provides the most trusted products available to manage the quality, workflow, analytics, and patient engagement in women’s imaging, did you know PenRad is also looking out for the health of its client’s business?  Managing the health of a patient is the primary goal of any physicians group or diagnostic [...]

Genetic Testing for Hereditary Cancers in Women’s Imaging. Now is the Time.

In the 1990’s when BRCA1 and BRCA2 were found to be associated with an increased risk of developing breast cancer, getting patients tested for these genetic mutations was difficult.  The thought of widespread testing of patients represented a nearly insurmountable challenge for a multitude of reasons.  Since that time genetic testing has become much more [...]


(#327) 3D mammography may shake ‘routine’ out of architectural distortion surgery (Radiology Business July 15, 2022)

“When counseling patients with architectural distortion on digital breast tomosynthesis (DBT) but no signs of malignancy on biopsy, mammographers should raise imaging alone as a sound option for surveillance.

So suggest breast radiology researchers at Massachusetts General Hospital who reviewed final diagnoses of 129 architectural distortions in 125 women imaged with digital 2D mammography as well as DBT.

All patients were seen at the authors’ institution, and all underwent surgical excision of lesions deemed nonmalignant at image-guided needle biopsy.”

(#326) AI/radiologist combo improves breast cancer detection, decreases workloads (Health Imaging July 11, 2022)

“A system that combines AI triage with the irreplaceable expertise of radiologists could save practitioners time and stress without sacrificing missed diagnoses in breast imaging.

The new two-part AI system is based on a decision-referral approach and triages mammograms based on quantification of uncertainty. When the system lacks the amount of sufficient assurance required to rule out suspicious findings, it refers the exam to a radiologist. The system’s performance was measured using a retrospective dataset of 1,193,197 digital mammography studies and compared to AI and radiologists as standalone interpreters.”

(#325) Ultrasound novices quickly master ‘volume sweep’ breast imaging  (Radiology Business July 10, 2022)

“In a new trial, medical students who were trained for two hours or less in an ultrasound “volume sweep” imaging (VSI) protocol obtained diagnostic-quality imaging of palpable breast lesions.

Interpreting the images, an attending breast radiologist diagnosed the findings with 97% sensitivity, 100% specificity and 97.6% agreement with standard-of-care imaging obtained by experienced sonographers using conventional protocols.

What’s more, the ultrasound machine used in the study was a portable handheld unit that retails for around $2,000.”

(#324) Breast MRI screening cuts cancer mortality rates in half for women with lesser-known gene mutations (Health Imaging February 18, 2022)

“New research recommends breast MRI for women with ATM, CHEK2 and PALB2 gene mutations.

Breast cancer mortality of women with lesser-known gene mutations could be cut in half if they were to undergo annual MRI screenings, according to new research published in JAMA Oncology.

BRCA1 and BRCA2 are the most widely known gene mutations among the general population. However, they aren’t the only mutations that carry an increased risk of invasive breast cancer. ATM, CHEK2 and PALB2 genes are collectively as common as BRCA1 and BRCA 2 but until recently, research pertaining to how to manage the alterations has been lacking.

This is what prompted researchers to explore screening guidelines for individuals in this high-risk demographic.”

(#323) CMS expanding coverage for low-dose CT lung cancer screening  (Radiology Business February 10, 2022)

“The Centers for Medicare & Medicaid Services is expanding coverage for low-dose CT lung cancer screening, the administration announced Thursday afternoon.

CMS’ final decision will expand eligibility for Medicare beneficiaries to receive such lifesaving screenings by dropping the starting age from 55 down to 50 years old. The agency will also reduce the tobacco smoking history threshold from at least 30 packs per year down to at least 20, according to an announcement.

“Expanding coverage broadens access for lung cancer screening to at-risk populations,” CMS Chief Medical Officer and Director of the Center for Clinical Standards and Quality Lee Fleisher, MD, said Feb. 10. “Today’s decision not only expands access to quality care but is also critical to improving health outcomes for people by helping to detect lung cancer earlier.””

(#322) Blood test helps more accurately predict which patients would benefit from CT lung cancer (Radiology Business January 11, 2022)

A novel blood test may help more accurately predict which patients would benefit from CT lung cancer screening, according to research published Friday in the Journal of Clinical Oncology.

Combined with a risk model that also factors in an individual’s smoking history, this approach could improve upon screening recommendations from the U.S. Preventive Services Task Force, experts noted. MD Anderson researchers estimate their model would pinpoint 9% additional lung cancer cases for screening while also reducing unnecessary imaging referrals by nearly 14% compared to USPSTF guidance.”

(#321AI could speed up CT lung cancer screening (AuntMinnie January 10, 2022)

“An artificial intelligence (AI) algorithm performs comparably to radiologists for reading low-dose CT (LDCT) lung cancer screening exams and could help reduce the workload in screening programs, according to a study published January 6 in Lung Cancer.

The ability to make CT lung cancer screening programs more efficient could be particularly helpful as demand ramps up due to expanded eligibility criteria, wrote a team led by Harriet Lancaster, PhD, of the University of Groningen in the Netherlands.”

(#320) Study Recommends Use of Ultrasound First for DBT-recalled Noncalcified Masses (Applied Radiology Dec 17, 2021)

“A study published in the American Journal of Roentgenology says that radiologists should consider performing ultrasound (US) first for digital breast tomosynthesis (DBT)-recalled noncalcified masses.

“Omitting diagnostic mammography when US is negative has a low false-negative rate,” wrote lead researcher Jessica H. Porembka, MD, from the University of Texas Southwestern Medical Center in Dallas. Noting that US alone is effective in diagnosing noncalcified masses recalled on screening tomosynthesis, “for asymmetries,” she explained further, “diagnostic mammography may be best without the need for additional US, while architectural distortions still warrant diagnostic mammography and US.””

(#319) Subjectivity remains a challenge among radiologists using BI-RADS 5 for breast density (Health Imaging Dec 13, 2021)

“A study published recently in Clinical Imaging revealed that subjectivity remains a challenge among radiologists assessing breast density using BI-RADS fifth edition guidelines.

The Breast Imaging Reporting and Data System (BI-RADS) guidelines were developed to categorize mammographic findings. As technology and research evolve, the recommendations are updated. However, research has revealed reader subjectivity as a long-standing nuisance of categorizing breast density.

“Although quantitative methods have been developed and are improving, density is mostly determined by radiologists’ visual assessment, which is subjective and prone to under- or over-estimation,” corresponding author, Leah H. Portnow, MD, with the department of radiology at Brigham and Women’s Hospital, and co-authors explained.”

(#318) Breast density associated with an increased risk of invasive cancer among women 75 and up (Radiology Business Aug 26, 2021)

“Breast density is associated with an increased risk of invasive cancer among women age 65 and up, according to a new prospective study published in JAMA Network Open.

Meanwhile, less-dense, fatty tissue was tied to a lower probability of this form of the disease across all age groups. Research has previously correlated breast density with invasive cancer risk among women age 40-65, but little data exists on the elder population, experts from more than a dozen institutions detailed Thursday.

Epidemiologist Shailesh Advani, MD, PhD, and co-authors believe their findings should help inform providers’ imaging strategies.”

(#317) Hunting for Hereditary Cancers (ClinicalOMICs April 9, 2021)

“When people think of what causes cancer, they probably think of smoking, too much sun, maybe even diet. Various carcinogens do drive genetic mutations that set off cancers. In some cases, though, someone’s genes at birth—the ones that make up a person’s germline genome—can cause cancer. According to Prasanth Reddy, senior vice president and enterprise oncology head of Labcorp’s oncology unit, about 5–10% of cancers are due to inherited risks.

In the past, scientists diagnosed hereditary cancers from family histories, but today’s oncologists can make use of a range of options, from cancer-related gene panels to complete genome sequencing. As Yuri Fesko, medical director of oncology medical affairs at Quest Diagnostics, says, “There have been great strides and advances in testing for hereditary cancer.” With expanded testing, though, scientists see some new complexities in these diseases.”

(#316) AI system successfully IDs colorectal cancer in whole slide images (AI in Healthcare Nov. 9, 2021)

“Researchers have designed a new AI-powered pathological recognition program that can identify signs of colorectal cancer as well as human specialists, sharing their findings in Nature Communications.

The team trained its program with more than 13,000 whole slide images of colorectal cancer from nearly 9,000 different patients who were originally treated in China, Germany or the United States. To test its effectiveness, the system was then used to detect colorectal cancer—and its performance was compared to that of trained pathologists.

The average pathologist scored an area under the ROC curve of 0.969. The AI system, meanwhile, achieved a score of 0.98.”

(#315) While promising, machine learning still misses 20% of cancers on breast MRIs, analysis shows (Health Imaging Nov. 5, 2021)

“Although promising, the benefits of using machine learning-based MRI for detecting axillary lymph node metastases in breast cancer patients fell short of earning expert recommendation, according to a new study published in Insights into Imaging.

Diagnosing axillary lymph node metastases (ALNM) can be difficult, but its detection is crucial in a patient’s treatment plan and prognosis. In recent years, MRI has emerged as a valuable imaging modality in breast cancer research, and MRI in conjunction with machine learning (ML) models has been shown to detect ALNM. However, until now, a thorough analysis of its accuracy had not yet been conducted.”

(#314) Updated lung cancer screening guidelines could spell 54% surge in LDCT imaging eligibility (Radiology Business Oct. 13, 2021)

“New lung cancer guidelines could spell a nearly 54% surge in eligibility for low-dose CT screening, with marked gains in minority populations, experts charged Tuesday in JAMA Network Open.

The influential U.S. Preventive Services Task Force just recently lowered the recommended starting age from 55 down to 50, among other changes, drawing praise from radiologists. Coupled with dropping the smoking history from 30 to 20 pack-years, Kaiser Permanente researchers believe these modifications could produce a 30% uptick in lung cancer diagnoses when compared with previous recommendations.”

(#313) FDA-approved PET agent helps solve 87% of diagnostic breast cancer dilemmas (Health Imaging Sept 29, 2021)

“A federally approved imaging agent can help radiologists and other physicians solve difficult diagnostic decisions for breast cancer patients, according to new data.

The estrogen receptor is a key feature of breast cancer and is expressed in 79% of tumors. While ER-positive patients will likely respond to therapy, clinical dilemmas arise when ER expression varies between tumors or if biopsies can’t be performed safely.

Dutch researchers found 18F-FES PET imaging can significantly help these patients. The technique assisted providers with 87% of scans, authors reported in the September issue of the Journal of Nuclear Medicine.”

(#312) Contrast-enhanced mammography as effective as MRI at evaluating newly diagnosed breast cancer (Radiology Business Aug. 30, 2021)

“Contrast-enhanced mammography is as effective as MRI for staging newly diagnosed breast cancer and can serve as a solid alternative for those facing barriers to the latter.

That’s according to a new prospective, single-center study from the University of Southern California, published Thursday in Clinical Imaging. Magnetic resonance has served as the gold standard for evaluating new breast cancers or additional disease, given its “superior” sensitivity, USC experts noted. However, it can pose new problems that include high costs, claustrophobia, and allergies to gadolinium imaging agents.

Contrast-enhanced spectral mammography utilizing iodine offers a sound alternative, illuminating lesions otherwise invisible on a regular mammogram. Testing it out on a multi-ethnic group of patients, enhanced mammography scored higher specificity and positive-predictive value than MRI, which is prone to overcalling benign lesions.”

(#311) Screening for hereditary breast and ovarian cancer at outpatient imaging centers ‘highly feasible’ (Radiology Business Aug. 25, 2021)

“Large-scale screening for hereditary breast and ovarian cancer during an outpatient imaging encounter is practical and “highly feasible,” MD Anderson Cancer Center experts charged in a new analysis.

Pathogenic mutations in breast cancer genes have been shown to increase a patient’s lifetime risk of getting diagnosed with these two forms of the Big C. Yet use of genetic evaluation remains “suboptimal,” researchers wrote Monday in Cancer.

To address this challenge, the noted Houston-based provider developed a questionnaire using National Comprehensive Cancer Network genetic counseling referral guidelines. Administering the form as part of mammography intake at a community imaging center, physicians found success.”

(#310) Most referring providers fine with radiologists delivering imaging results; some patients remain hesitant (Health Imaging, July 9, 2021)

“There’s been a recent push to increase radiologists’ visibility by communicating results directly to patients. But new research shows providers and patients don’t see eye-to-eye on this topic, suggesting an individualized approach for delivering findings may be best.

Imaging results are presented in many ways, including via web portals, from referring physicians, nurse coordinators or radiologists. One thing is certain, however: there’s no universal agreed-upon approach, Weill Cornell Medicine experts explained Friday in JACR.

Hoping to find a solution, the New York-based practitioners surveyed 192 referrers and 258 patients as they came in for CT lung cancer screening exams. Most were OK with radiologists delivering both normal and abnormal results, but it isn’t that straightforward.”

(#309) One-third of patients do not receive timely follow-up after their CT lung cancer screening (Radiology Business, July 8, 2021)

“Less than two-thirds of patients receive timely follow-up care after a low-dose CT lung cancer screening, according to a new large-scale analysis published Thursday in JAMA Network Open.

Delays or lack of follow-through were more pronounced among Black, low-income, or patients with mental health disorders. Lung disease is the leading cancer killer worldwide and CT screening has been proven to reduce mortality. However, providers must stick to the recommendations spelled out in the American College of Radiology’s Lung-RADS recommendations to achieve such success, authors advised.”

(#308) Performance in Screening Mammography Predicted by Radiologist Characteristics (Applied Radiology June 24, 2021)

“A new study by the Harvey L. Neiman Health Policy Institute and the American College of Radiology’s National Mammography Database Committee reports the most influential radiologist characteristics impacting mammography interpretive performance were geography, breast sub-specialization, performance of diagnostic mammography and performance of diagnostic ultrasound.

Published in Radiology, the study examined 11 years of screening mammography performance metrics from the National Mammography Database (NMD). From this data, the researchers found that radiologists in the West or Midwest, breast subspecialists, and those who perform diagnostic mammography were more likely to achieve acceptable performance across a range of metrics…”

(#307) ACR, Society of Breast Imaging issue updated guidance for screening women with average cancer risk (Radiology Business June 21, 2021)

“The American College of Radiology and Society of Breast Imaging recommend that women begin receiving annual mammograms at age 40, with added vigilance for those in historically overlooked populations.

Both shared updated guidance in the Journal of the American College of Radiology on June 18. Their recommendations are based on an “extensive” data from randomized controlled trials and peer-reviewed literature.

“Since our most recent guideline, new data are available to evaluate the impact of screening using advanced-stage and fatal breast cancers, to assess the utilization and benefits of [digital breast tomosynthesis], and to evaluate disparities in breast cancer screening and treatment among minority women,” Debra Monticciolo, MD, vice chair of the department of radiology and section chief of breast imaging at Baylor Scott & White Medical Center-Temple, and co-authors wrote Friday. “With this guideline, we offer recommendations more inclusive of all women of average risk for breast cancer.””

(#306) Treating pure ground glass nodules is not a cost-effective strategy, large-scale analysis finds (Radiology Business June 15, 2021)

“Treating pure ground glass nodules is not a cost-effective strategy for imaging practices, according to a new large-scale analysis published Tuesday in Radiology.

Members of the specialty are increasingly identifying such lesions on chest CT, including in about 9% of patients undergoing lung cancer screening. Subsolid nodules have a high risk of becoming malignant, but they also grow slowly and have low potential of metastasizing, noted lead author Mark Hammer, MD.

“This may almost seem like a contradiction, but it presents a problem: How should we choose when to treat these (potential) cancers,” Hammer, a thoracic radiologist at Brigham and Women’s Hospital and assistant professor at Harvard, told Radiology Business by email. “If we address all of the cancers, we will probably end up overtreating a lot of patients who would have died with rather than of these cancers. So, we wanted to see if we can understand when to treat these lesions.””

(#305) Pioneering Single-dose Radiotherapy for Breast Cancer Treatment (Imaging Technology News June 2, 2021)

“A breast cancer therapy that requires just one shot of radiotherapy is as effective as traditional radiotherapy, and avoids potential damage to nearby organs, according to a paper by UCL experts.

The results, published in the British Journal of Cancer, mean that eight out of ten patients who receive the treatment, TARGIT-IORT, will not need a long course of post-operative external beam radiotherapy (EBRT).[1] These results strengthen and expand previously published outcomes.

Patients who received the treatment are less likely to go on to experience fatal cardiovascular disease such as heart attacks, lung problems or other cancers. As well as avoiding scattered radiation from EBRT that can damage nearby vital organs, delivering TARGIT-IORT during the lumpectomy procedure seems to lower the likelihood of death if patients do go on to develop cardiovascular disease, protecting in a drug-like manner. This was the case even when EBRT was also given post-operatively, and is thought to be because the treatment changes the microenvironment in the lumpectomy wound.”

(#304) One-quarter of severe COVID-19 patients retain lung problems 1 year after discharge, CT scans show (Health Imaging May 6, 2021)

“Up to one-third of patients with severe COVID-19 still have lingering lung effects up to one year after they were hospitalized, researchers reported Wednesday in the Lancet Respiratory Medicine.

Scientists have made significant progress in understanding and treating the coronavirus, but there’s little insight into how long it takes patients to fully recover. Many COVID long-haulers still report symptoms long after they’re discharged.

Over the course of 12 months, most of the 83 patients enrolled in this study fully recovered. But one-third still showed reduced lung function and nearly one-quarter retained lung abnormalities on their CT scans, the authors reported May 5.”

(#303) With Lymph Node Abnormalities, Consider Tattoo History (Diagnostic Imaging May 3, 2021)

“Tattoo ink can migrate in female patients, potentially mimicking lymph node findings on breast imaging.

Tattoos do more than change a patient’s outward appearance. The ink used can also change the internal appearance, as well – specifically creating the appearance of lymph node abnormalities.

In a study released on April 30 in Clinical Imaging, investigators from Weill Cornell Medicine outlined how tattoo ink can migrate over time and can mimic these radiographic findings. Based on what they saw on four mammographic cases, the team led by Michele B. Drotman, M.D., a breast imaging specialist, tattoo ink can show up on screening scans as abnormal high-density material in axillary lymph nodes, mimicking calcifications.”

(#302) Risk of Lung Cancer Linked to Specific Variants (ClinicalOMICs March 19, 2021)

“A new study from researchers at Institute for Clinical and Translational Research (ICTR) at Baylor University highlights specific variants and how they contribute to increased risk of lung cancer.

The study, which included whole-exome sequencing on germline (inherited) DNA from eight large-scale datasets, including 1,045 patients with a family history of lung cancer or early-onset cancer. Those groups are more likely to harbor genetic risk variants. The analysis also included 885 control cases.

“We were looking for variants that have a relatively high impact on risk but occur at relatively low frequency,” said. Chris Amos, corresponding author of the study, professor of medicine – epidemiology and population sciences and director of the Institute for Clinical and Translational Research (ICTR) at Baylor. “If a variant occurs at low frequency, you have to look at many different large data sources to validate the variant. These results can be replicated in many different European populations.””

(#301) Contrast-Enhanced Mammography Equivalent to MRI for Breast Cancer Detection in Women with Implants (Diagnostic Imaging March 21, 2021)

“An emerging breast imaging technique – contrast-enhanced mammography (CEM) – performs equally as well as breast MRI in identifying breast cancers in women who have had breast augmentation.

In the first study to investigate how well CEM, which uses iodine to highlight tumor neurovascularity, performs in women who have breast implants, investigators from the Mayo Clinic said their findings show this new imaging option can work for women who either do not have access to MRI or who cannot undergo the scan for a variety of reasons, such as having a pacemaker.

The team, led by Mayo Clinic diagnostic radiology resident Molly Carnahan, M.D., published their findings on March 18 in the American Journal of Roentgenology.”

(#300) ACR slams JAMA mammography study, editorial over ‘outrageous and insulting’ claims (Radiology Business March 15, 2021)

“The American College of Radiology slammed new JAMA research and a corresponding editorial on Monday over “outrageous and insulting” claims related to breast imaging.

In a research letter published March 15, Weill Cornell Medicine scientists estimated that 87% of specialized breast cancer centers in the U.S. provide screening recommendations that differ from national societies. That included an average start date of 40 years, with 81% of centers advising annual screening.

Only about 12% of breast cancer centers highlighted the importance of shared decision-making between a woman and her primary care doc. In a corresponding editorial University of California, San Francisco, experts criticized these findings and breast imaging providers for operating based on “nonevidence-based” guidelines.”

(#299) iCAD Announces FDA Clearance for ProFound AI Version 3.0 for 3D Mammography (Nasdaq March 15, 2021)

“iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that ProFound AI® Version 3.0 for Digital Breast Tomosynthesis (DBT) was cleared by the U.S. Food and Drug Administration (FDA). Compared to previous versions of the software, the ProFound AI 3.0 algorithm offers up to a 10% improvement in specificity performance and up to 1% improvement in sensitivity.1 ProFound AI Version 3.0 also offers up to 40% faster processing on the new PowerLook platform.1”

(#298) Simple, readily available MRI measurement could reduce breast biopsies by one-third (Radiology Business March 4, 2021)

“A simple, readily available MRI measurement could potentially reduce breast biopsies by almost 33%, according to a new study out of Austria.

MRI is an oft used means of detecting and classifying tumors, but it can sometimes result in false positives leading to unnecessary biopsies, excess costs and overtreatment. Scientists with the University of Vienna, however, have validated a noninvasive imaging biomarker they say can reduce biopsies after MRI.

The practice change would only take about three minutes, can be incorporated into standard short-MRI scans, and uses infrastructure that exists in most radiology practices. Diffusion-weighted imaging is already established in stroke care and is becoming increasingly popular in cancer diagnostics.”

(#297) Radiology practice helps administer COVID-19 vaccinations using its mobile mammography units (Radiology Business Feb 23, 2021)

“A Texas radiology practice is lending its mobile mammography vehicles to help administer COVID-19 vaccinations in hard-to-reach parts of the Lone Star state, officials revealed this week.

Desert Imaging plans to partner with El Paso County and University Medical Center to transport doses of the lifesaving drug to vulnerable members of the community. The radiology practice has three Mammos on the Move units available which they’ll use to target “super seniors” age 75 and older at assisted living, nursing home and adult day care facilities.

Director of Business Development Shane Griffith, MBA, said the locally owned practice was “all ears” when county officials approached about the potential partnership.”

(#296) Radiologists must work to standardize breast calcification reporting or advocates may intervene (Health Imaging Feb 18, 2021)

“Few radiologists consistently include breast arterial calcification findings in their mammography reports, according to evidence published Wednesday. And for providers who do indicate BACs, nearly two-thirds make no follow-up recommendations.

The findings come by way of the American College of Radiology, which surveyed nearly 600 of its members this past September.

Many studies have proven breast calcium deposits are associated with cardiovascular disease and coronary artery calcification, researchers explained Feb. 17 in Academic Radiology. Yet only 41% of respondents said they report BAC “always” or “most of the time.””

(#295) Intermountain radiologists asking women to schedule mammograms around their COVID-19 vaccinations (Health Imaging Feb 9, 2021)

“One of the largest providers in the Western United States is telling patients to schedule their annual mammograms around receiving COVID-19 vaccinations to avoid being misdiagnosed with breast cancer due to vaccine side effects.

Intermountain Healthcare recently followed other health groups around the country with their new guidance, now encouraging women to either get their breast screening exam before being vaccinated or wait at least one month after their final dose.

The new policy is based on the nearly 11% of patients who show swollen lymph nodes on their scan after receiving the initial dose of vaccine, and 16% after the second. Such findings would typically indicate metastatic cancer and require a biopsy, Brett Parkinson, MD, medical director of Intermountain’s Breast Care Center, told the Desert News on Tuesday.”

(#294) Analysis finds significant variation in radiologists’ follow-up recommendations for lung nodules (Radiology Business Feb 9, 2021)

“There is widespread variation in whether radiologists make a follow-up recommendation for pulmonary nodules, and organizations may need to consider changes to help alter this behavior.

That’s according to a new single-center analysis out of Brigham and Women’s Hospital, published Sunday in JACR. Lung cancer is the deadliest form of the disease in the U.S., and pulmonary nodules are one of the most common reasons for repeat CT exams. Practice guidelines help dictate how radiologists should respond in such scenarios, noted experts with the Boston-based institution. Yet, Brigham found significant differences in the probability of making a follow-up recommendation among physicians in the same subspecialty division.”

(#293) Breast Cancer Tops Lung Cancer for No. 1 Diagnosis Worldwide (Diagnostic Imaging Feb 5, 2021)

“Breast cancer in women has leap-frogged lung cancer, now accounting for the most cancer diagnoses worldwide – and the situation is likely to get worse in coming decades.

In a report published Feb. 4 in CA: A Cancer Journal for Clinicians, dubbed the “Global Cancer Statistics 2020,” the American Cancer Society (ACS) and International Agency for Research on Cancer (IARC) shared their findings based on data from the Global Cancer Observatory.

Based on their analysis, there were 19.3 million new cancer cases diagnosed in 2020, 2.3 million – 11.7 percent – of which were female breast cancer. In fact, it is now the No. 1 cancer identified in 159 of 185 countries included in the report.”

(#292) COVID-19 vaccine update: Radiologists report side effects mimicking breast cancer on mammograms (Health Imaging Feb 4, 2021)

“Radiologists are reporting a COVID-19 vaccine side effect that may trick some doctors into diagnosing a patient with breast cancer, Fox 8 Cleveland reported Wednesday.

University Hospitals Cleveland Medical Center said it has been seeing a high number of women with swollen lymph nodes, or axillary adenopathy, on their mammograms over the past few weeks. While such inflammation is the body’s normal response to the vaccine, it may be mistaken for something more serious.

“We also see swollen lymph nodes in patients with breast cancer, so that’s the concern there,” Holly Marshall, MD, a breast radiologist at the Cleveland-based health system, told the news outlet. “So we are asking everybody who is having a mammogram if they had the COVID-19 vaccine, what dose, when, and what side.””

(#291) Casana raises $14M to bring toilet seat-based heart monitoring system to market (Cardiovascular Business Feb 3, 2021)

“Casana, a Rochester, New York-based healthcare technology company, announced that it has raised $14 million in Series A funding. The money is expected to go toward bringing to market the company’s first solution, a toilet seat-based cardiovascular health monitoring system.

The Heart Seat is a cloud-connected device that tracks a user’s cardiovascular health, saving data so that physicians can gain a greater picture of how symptoms are progressing over time.

Casana also announced that Austin McChord is now the company’s CEO.

“Our goal is to be able to monitor a patient’s health more naturally at home, without interruption of their daily routine,” McChord said in a statement. “The toilet seat is not a tech gadget. Unlike a wearable device, you can’t take it off, forget to use it or mess it up. If we do our job right, when patients use our effortless in-home heart monitoring device, we are invisible unless their health status needs attention.””

(#290) PET Imaging Reveals Which Breast Cancer Patients Won’t Respond to Hormone Therapy (Diagnostic Imaging Feb 3, 2021)

“The answer to whether hormone replacement therapy will work for a woman with breast cancer likely comes down to whether her estrogen receptors are working – a function that can be clearly seen via PET imaging.

Roughly 80 percent of the approximately 250,000 cases of breast cancer diagnosed annually in the United States are labeled as estrogen receptor-positive. Hormone therapy is commonly used to treat this group because it can impede estrogen’s effect on tumors. But, it only works in about half of cases, leaving providers wondering how to identify which women will benefit and who will not.

To help doctors figure out which patients are good hormone therapy candidates, a team of investigators from the Washington University School of Medicine at St. Louis launched a trial, and they discovered the treatment does not work in women with non-functional estrogen receptors.”

(#289) Low-Dose CT Screening Benefits Never-Smokers, Too (Diagnostic Imaging Feb 1, 2021)

“Low-dose CT (LDCT) screening for lung cancer does not benefit smokers alone. It can also be used to successfully screen patients who have never smoked for the disease.

During the International Association for the Study of Lung Cancer 2021 World Conference this weekend, investigators from Taiwan revealed data that shows LDCT screening can identify the presence of lung cancer in individuals who have never actively smoked, but who are still at high-risk for the disease.

Existing studies, including the National Lung Cancer Screening Trial (NLCST) and NELSON Trial have already demonstrated LDCT’s role with smokers, but with 10 percent-to-15 percent of lung cancer cases developing in non-smokers, being able to detect disease in this group is critical.”

(#288) ‘Significant discrepancy’ between radiologists, emergency docs hurting follow-up for incidental (Health Imaging Jan 29, 2021)

“Incidental findings are on the rise in radiology, with nearly one-quarter of imaging exams producing masses unrelated to a patient’s initial test. Many health systems, however, struggle with closing the care loop after spotting these potentially cancerous abnormalities.

There are a host of reasons for this, including inconsistent communication between radiologists, ordering providers, emergency physicians, and patients. And new research published Friday in JACR took a look at this problem.

Surveying nearly 400 rads and emergency physicians, most did agree on the importance of incidental masses and the need to follow-up on them, but both physician groups also indicated only a minority of organizations are taking active steps to do so.”

(#287) Radiology’s input on new USPSTF breast cancer screening plan is ‘critical,’ ACR (Health Imaging Jan 28, 2021)

“The United States Preventative Services Task Force has opened a public comment period for its new breast cancer screening research plan, and radiology’s input on the topic is “critical,” the American College of Radiology said Thursday.

Last week, the USPSTF published its draft document and said it would be open to feedback through Feb. 17. The document outlines its planned research approach, including study features and criteria, that will be used to determine new breast screening recommendations.

The American College of Radiology, meanwhile, called on radiology as a specialty to offer up guidance. ACR noted that its Breast Imaging Government Relations Committee, Breast Imaging Commission, and Screening Leaders group will be reviewing the draft to inform its own comments.”

(#286) 35% of patients recovered from severe COVID-19 show potentially irreversible lung damage at CT follow-up (Health Imaging Jan 27, 2021)

“The coronavirus pandemic has claimed more than 2 million lives worldwide, often due to severe lung damage and breathing problems.

For those who do survive, many carry long-term pulmonary abnormalities. But doctors are still left with more questions than answers when it comes to these COVID-19 long-haulers.

In a bid to help close this knowledge gap, a group of U.S. and Chinese researchers on Tuesday published six-month follow-up chest CT findings in patients recovered from severe COVID-19 pneumonia.”

(#285) COVID-19 Vaccine-Linked Adenopathies Could Mimic Breast Malignancies (Diagnostic Imaging Jan 20, 2021)

“It is important for radiologists to consider recent COVID-19 vaccination history as a possible differential diagnosis for patients with unilateral axillary adenopathy,” the team said. “As COVID-19 vaccines will soon be available to a larger patient population, radiologists should be familiar with the imaging features of COVID-19 vaccine induced hyperplastic adenopathy and its inclusion in a differential for unilateral axillary adenopathy.”

(#284) Not Just BRCA: Large Studies ID Other Key Breast Cancer Risk Genes (MedPage Today Jan 20, 2021)

“Two large breast cancer case-control studies of women from the United States, Europe, and Asia identified eight genes that had significant associations with breast cancer risk — BRCA1, BRCA2, PALB2, ARD1, RAD51C, RAD51D, ATM, and CHEK2.

Both studies were published in the New England Journal of Medicine. The first, by Fergus J. Couch, PhD, of the Mayo Clinic in Rochester, Minnesota, and colleagues, looked at a panel of 28 cancer-predisposition genes in approximately 64,000 women from the United States (32,247 with breast cancer).”

(#283) Overaggressive lung nodule evaluation saddling patients with excess costs, radiation exposure (Radiology Business Jan 19, 2021)

“Overaggressive evaluation of incidentally detected lung nodules may be saddling patients with excess costs and unnecessary radiation exposure, according to a study published Tuesday in JAMA Internal Medicine.

Each year, U.S. providers spot small masses in roughly 1.6 million individuals, with only about 5%-10% actually ending up with lung cancer, noted experts with several West Coast institutions. Guidelines recommend varying types of responses in these situations aligned with a patients’ risk for the disease and nodule size, and yet adherence rates for these recommendations can run as low as 39%.

Wanting to better understand the ramifications for such evaluations, Farhood Farjah, MD, MPH, and colleagues conducted a comparative-effectiveness research study incorporating more than 5,000 patients. They found that higher-intensity diagnostic evaluation resulted in greater radiation exposure, more procedure-related adverse events and higher health costs.”

(#282) Hybrid lung cancer screening program could save Medicare millions in follow-up spending (Health Imaging Jan 19, 2021)

“A new strategy for managing nodules during baseline lung cancer screening could eliminate many unnecessary follow-up visits and slash Medicare spending by millions, according to new estimates published Tuesday.

The technique combines the Lung CT Screening Reporting and Data System (Lung-RADS) with artificial intelligence-based malignancy risk scoring to improve the accuracy of screening exams. Using the AI-informed strategy ballooned specificity to 96% up from 66% when using Lung-RADS alone, Canadian researchers explained in JACR.

And after comparing the cost differences between Lung-RADS-recommended follow-up procedures to the hybrid management strategy, the researchers found the latter would save, at a minimum, $72 per patient and a maximum of $242 per person.”

(#281) Dense Breast Notification Laws Falling Short of Hopes (Diagnostic Imaging Jan 13, 2021)

“Dense Breast Notification (DBN) legislation – the laws requiring that women be notified after a mammogram about their level of breast density – are working, just not as well as hoped.

According to a nationwide study conducted by investigators from Boston University School of Medicine (BUSM), women who live in states with DBNs are more well informed about breast density, and more of them are talking to their doctors about it. But, the overall rates still remain low.

To find out why, the team, led by Nancy Kressin, Ph.D., BUSM professor of medicine, looked at whether sociodemographic characteristics could be playing a role. They published their findings recently in the Journal of the American College of Radiology.”

(#280) Inpatient mammograms may help reduce disparities in breast cancer screening (Health Imaging Jan 13, 2021)

“Lower-income individuals often face a number of socioeconomic factors preventing them from completing breast cancer screening exams, including transportation and work issues. But Massachusetts General Hospital providers may have come up with a plan to ensure these patients receive the care they need.

Their pilot study, detailed in the January issue of the Annals of Family Medicine, involves performing mammograms when patients are first admitted to the hospital. National and local data both indicate that women covered under both Medicaid and Medicare have low rates of breast screening.

Screening these dual-eligible patients in the inpatient setting, however, proved not only to be feasible, but successfully targeted those who would likely have not, or never had, undergone a mammogram.”

(#279) A COVID silver lining: Pandemic-related workflow changes produce 23% drop in imaging wait times (Radiology Business Jan 5, 2021)

“While the COVID-19 pandemic has posed considerable challenges to the radiology profession, it may have also produced a few positives, too, according to an analysis published Monday.

The crisis has forced many providers to implement workflow changes that include screening patients when they schedule an appointment or encouraging them to complete registration forms online. At NYU Langone Health in New York City, these practice modifications have resulted in measurable efficiency gains, experts wrote in Academic Radiology.

Across the system’s 17 busiest outpatient imaging centers, NYU has seen a 23% drop in pre-exam wait times (or about 6.8 minutes), with patients’ overall time spent on-site dropping by 15% (8 minutes).”

(#278) Offering same-day cancer risk assessments, genetic testing to boost a breast imaging practice’s value (Radiology Business Dec 18, 2020)

“Breast imaging centers can also offer same-day risk assessments and genetic testing programs to add value beyond traditional radiology services.

That’s according to a new study out of Banner MD Anderson Cancer Center, published Wednesday in Academic Radiology. Women are often under screened for these pathogenic mutations, and seldom receive the genetic counseling that follows.

Wanting to address this challenge, MD Anderson piloted radiology-operated, proactive, same-day risk assessments and genetic testing to help diagnose high-risk women also undergoing imaging. Bottom line: The add-on proved feasible, increasing value for patients through better clinical outcomes and lower costs.”

(#277) ACR seeks input in effort to address radiology’s deadly incidental findings (Radiology Business Dec 16, 2020)

“The American College of Radiology is seeking input from the field in its effort to address incidental findings care gaps that can result in patient harm or death.

ACR recently scored a $341,000 grant from the prestigious Gordon and Betty Moore Foundation to develop a quality measure set for unexpected abnormalities in imaging studies. With the Closing the Results Follow-up Loop on Incidental Findings project now moving to the next phase, college leaders are seeking feedback from patients and rads on their work.

In an announcement shared Monday, ACR said it sees “tremendous opportunities” to improve imaging follow-up care, once its work is complete.”

(#276) Only One-in-Three Breast Cancer Patients Offered Potentially Life Saving Genomic Test (ClinicalOMICs Dec 9, 2020)

“A study carried out by Massachusetts health tech company Outcomes4Me suggests that less than 30% of advanced breast cancer patients are undergoing genomic testing that could improve their treatment outcomes.

Of those that were not tested, only 50% appeared to have any awareness that genomic testing was an option. However, when more information was offered almost 90% were keen to undergo testing to help guide their treatment.”

(#275) ACR experts advising President’s Cancer Panel on boosting breast imaging numbers post-COVID-19 (Radiology Business Nov. 18, 2020)

“Two American College of Radiology industry experts are advising the President’s Cancer Panel on ways to boost breast imaging rates during the pandemic and beyond, the group announced Monday.

They include Chief Research Officer Etta Pisano, MD, along with Michigan Medicine professor Ruth Carlos, MD, editor-in-chief of JACR. The two are taking part in virtual panels running through Thursday on ways to bring innovation into imaging amid widespread slowdowns.

“The COVID pandemic has unfortunately reduced access to breast cancer screening, which may exacerbate already significant disparities in breast cancer outcomes,” Pisano, who is also chair of the high-profile Tomosynthesis Mammographic Imaging Screening Trial, said in a statement. “I look forward to contributing to this very important discussion,” she added later.”

(#274) 94% of patients at high risk for lung cancer failed to undergo LDCT (Radiology Business Nov. 18, 2020)

“Out of an estimated population of 8 million at high risk for lung cancer, only 5.7% underwent low-dose CT screening in 2019, according to a new report published Tuesday.

There is also widespread imaging variation in this patient population from one state to the next, with rates as high as 18.5% in Massachusetts, down to 1% in Nevada. The numbers highlight the daunting task radiologists and other providers must tackle to begin addressing this “silent killer,” according to the American Lung Association’s third annual report on the disease.

“The ‘State of Lung Cancer’ highlights that too many people are being left behind when it comes to making progress against lung cancer,” ALA President and Chief Executive Officer Harold Wimmer said in a statement. “To turn the tide against this deadly disease, Congress needs to protect and expand access to quality and affordable healthcare that helps more people who may be at high risk get screened and ensures that those diagnosed have access to treatment.””

(#273) Less than 1 in 20 eligible adults receives LDCT screening for lung cancer (Health Imaging Nov. 12, 2020)

“Lung cancer screening rates are slowly increasing, but still, less than 1 in 20 eligible adults receives a low-dose CT exam in the United States, according to new figures published on Thursday.

Researchers led by the American Cancer Society used data from a national lung cancer registry for their findings, published in JNCI: The Journal of the National Cancer Institute. The team noted that utilization rose slightly from 3.3% in 2016 to 5% in 2018, but still remains relatively low.

Stacey Fedewa, PhD, with the ACS, also pointed out that state-level screening rates are not aligned with disease burden in many regions.”

(#272) Fast MRI an ‘effective and feasible’ option for detecting cancer in dense breasts (Radiology Business Oct 28, 2020)

“Abbreviated magnetic resonance imaging is an “effective and feasible” option for detecting cancer in dense breast tissue, with reimbursement also starting to follow suit, Penn Medicine researchers reported this week.

Scientists from the Philadelphia-based institution recently explored the use of such “fast MRI” on nearly 500 women who fall into this category. AB-MR, as it’s called for short, detected 13 additional cancer cases that digital breast tomosynthesis missed on the first go, the university announced on Tuesday.

With Pennsylvania and Missouri recently passing legislation stipulating that insurers must cover such supplemental screenings, the future may be bright for these examinations, researchers noted.”

(#271) ACR addresses anxiety around radiology report access under new information-blocking rules (Health Imaging Oct 27, 2020)

“The American College of Radiology on Monday sought to clear up confusion among imaging providers regarding upcoming federal interoperability regulations.

Specifically, the ACR said it’s fielding many similar questions on whether releasing rad reports via patient portals after a specified period of time will constitute information blocking. While this practice is largely considered medically necessary, as it stands, there is no specified ruling on the topic, the ACR noted.

“It is currently unknown whether HHS investigators would view providers’ medically appropriate patient communication policies as meeting the information blocking definition if reported in the future,” the ACR said in its statement.”

(#270) CytoPAN—Portable cellular analyses for rapid point-of-care cancer diagnosis ( Aug. 5, 2020)

“Accurate and timely diagnosis and categorization of cancer are not always simple even under optimal conditions, and it can be near impossible in the developing world, where the necessary specialists and equipment may not be available and biopsy results can take months to return. To address this diagnostic bottleneck, Min et al. devised an automated image cytometry system named CytoPAN, which can correctly detect breast cancer and identify its subtype in 1 hour using samples obtained by fine needle aspiration, a less invasive technique than core biopsy. The system is relatively affordable and requires minimal training, which should decrease the barriers to access in low-resource areas.”

(#269) Experimental DBT protocol slashes radiologists’ read times while retaining accuracy (Health Imaging October 7, 2020)

“A new experimental protocol reduced radiologists’ digital breast tomosynthesis interpretation times without sacrificing diagnostic accuracy, according to a new study.

University of Michigan Health System researchers shared their experience, using 6 mm slabs with a 3 mm overlap instead of 1 mm slices, Tuesday in Radiology. Compared to standard protocols, the new approach lowered mean DBT read times for three of four experienced breast radiologists without overlooking additional cancers.

The new thickness protocol may be an effective tool in relieving overworked imaging experts, Akshat C. Pujara, MD, with the Ann Arbor, Michigan, institution’s Department of Radiology and colleagues noted.”

(#268) New mammoscope tool bolsters cancer screening in women with dense breasts (Health Imaging September 29, 2020)

“University at Buffalo researchers have received a new grant to develop a portable mammography system that promises to improve cancer screening in women with dense breasts.

The team calls the new tool a dual scan mammoscope (DSM), which pairs light and ultrasound technologies to better spot breast cancers. It’s backed by a four-year, $1.4 million grant from the National Institutes of Health Institute of Biomedical Imaging and Bioengineering, the university announced Monday.”

(#267) Closing the Loop on Unexpected Findings  (Radiology Business Oct/Nov Digital Issue 2020)

“Follow-up of unexpected findings in radiology reports has becoming a growing challange as more imaging exams are being performed and workloads are increasing for ordering phsycians…”

(#266) Pre-Operative MRI Catches More Cancers in Women with Dense Breasts  (Diagnostic Imaging Oct 20, 2020)

“Pre-operative MRI can catch more breast lesions in women with dense breasts who have receive their initial breast cancer diagnosis via digital breast tomosynthesis (DBT).

Together, investigators from a multi-institutional team determined that pre-operative MRI does perform differently between women who undergo DBT and those who have digital mammography (DM). They shared their results in the Oct. 13 Clinical Imaging.”

(#265) GE Healthcare Captures FDA Clearance for Industry-First Contrast-Enhanced Mammography Biopsy (Diagnostic Imaging Oct 20, 2020)

“Introduced during RSNA 2019, GE Healthcare’s Serena Bright™ — the industry’s first contrast-enhanced biopsy solution for mammography – received 510(k) clearance Tuesday from the U.S. Food & Drug Administration.

This technology enables providers to perform contrast-guided breast biopsies without changing mammography equipment, rooms, or staff after a screening or diagnostic mammogram. Results, company officials said, can be available a few days rather than the several weeks needed for an MRI biopsy.”

(#264) Terahertz imaging IDs early stage breast cancer without sample staining (Health Imaging Oct 20, 2020)

“A new technique utilizing terahertz waves proved capable of imaging breast cancer without tissue sample staining, according to new research.

Experts out of Osaka University in Japan, the University of Bordeaux and the Bergonié Institute in France said their advanced method imaged early-stage samples smaller than 0.5 mm, which is difficult even under pathological analysis

Their work overcomes the time-intensive staining process and immense difficulty clinicians face in distinguishing ductal carcinoma in situ (DCIS) from malignant invasive ductal carcinoma. And even with their advanced approach, it was initially hard to diagnose one from the other, lead author Kosuke Okada, with Osaka University, noted.”

(#263) Patients more likely to choose LDCT lung cancer screening after meeting with radiologists versus other clinicians (Health Imaging Oct 19, 2020)

“Patients who sat down with a radiologist to discuss low-dose CT lung cancer screening more often chose to follow through with the exam than those who met with another type of clinician, according to new research.

In fact, Medicare enrollees who participated in a shared-decision making (SDM) visit with an imaging expert were nine times more likely to undergo low-dose computed tomography screening.

At the same time, University of Texas Medical Branch at Galveston authors found lower LDCT screening rates following SDM visits between patients and doctors who were familiar with one another.”

(#262) MRI-based technique may surpass invasive biopsies for analyzing breast cancer treatment effectiveness (Health Imaging Oct 6, 2020)

“A new MRI-based imaging technique can quickly determine if breast cancer treatments are working effectively, according to a recently published study.

The approach, known as hyperpolarization, magnetizes molecules in a strong magnetic field to assess whether cancer drugs are limiting tumor growth. While the method has only been tested in mouse models thus far, University of Cambridge researchers believe it may eventually replace invasive tissue biopsies.”

(#261) A ‘drastically different’ Pinktober for breast radiologists and patients than years past (Radiology Business Oct 2, 2020)

“The conclusion of September holds special meaning in breast imaging, but this year’s Pinktober is “drastically different” from previous iterations, experts say.

Widespread shutdowns of mammography screening services during the COVID-19 pandemic have left thousands of women in danger. One recent analysis out of the United Kingdom’s largest breast cancer charity estimated a backlog of 1 million women requiring screenings across the country. Another predicted upward of 10,000 excess deaths in the U.S. due to postponed colon and breast cancer imaging.

All of this has radiology advocacy groups urging the field to be on high alert during 2020’s Breast Cancer Awareness Month.”

(#260) A new, improved way to predict breast cancer risk with AI (Radiology Business May 7, 2019)

A new deep learning model leveraging data from screening mammograms can predict a patient’s breast cancer risk with significant accuracy, according to a new study published in Radiology. The authors noted that their technique outperformed the popular Tyrer-Cuzick breast cancer risk model.

Researchers from Massachusetts General Hospital (MGH) in Boston and the Massachusetts Institute of Technology (MIT) in Cambridge collaborated on the risk model, which combines deep learning and risk factors associated with the patient to make its assessments. Data from more than 88,000 consecutive screening mammograms was used to train, validate and test its performance.

“There’s a very large amount of information in a full-resolution mammogram that breast cancer risk models have not been able to use until recently,” lead author Adam Yala, PhD candidate MIT in Cambridge, Massachusetts, said in a prepared statement. “Using deep learning, we can learn to leverage that information directly from the data and create models that are significantly more accurate across diverse populations.”

(#259) Radiology can reduce CT lung cancer screening false positives by tackling these 2 factors (Radiology Business September 3, 2020)

“Scientists have demonstrated low-dose CT’s effectiveness in diagnosing lung cancer and saving lives. But the proven practice can go awry due to false positives—ballooning costs and patient anxiety in the process.

Wanting to better understand the factors that influence these mistakes, Harvard Medical School imaging experts recently delved into their data. Analyzing information from more than 3,700 patients logged over a four-year period, several sources bubbled to the surface, researchers wrote Thursday in Academic Radiology.

Those included patient-related factors such as income level, age or a previous diagnosis of chronic obstructive pulmonary disease. But it was two issues—radiologist inexperience and screening institution—that provide the greatest prospects for improvement, concluded Mark Hammer, MD, with Boston-based Brigham and Women’s Hospital.”

(#258) Less than 40% of providers adhere to radiologists’ follow-up recommendations for incidental findings (Health Imaging August 25, 2020)

“As imaging quality and utilization both continue to increase, the total number of incidental findings follows closely behind. But new research suggests adherence to recommended follow-up exams for these discoveries are highly dependent on care setting and provider type.

That’s what doctors discovered at the University of California, Davis Medical Center after analyzing hundreds of CT radiology reports completed over a six month period. Overall compliance with additional imaging suggestions proved to be near reported averages, with primary care providers and outpatient sites most likely to perform such exams.

Writing Tuesday in JACR, Shan S. Hansra, MD, with the Sacramento, California, institution noted referring physicians are typically responsible for handling rad report recommendations. But when incidental nodules or lesions fall through the cracks, downstream consequences are likely to arise.”

(#257) 60% of breast cancer survivors’ imaging care delayed due to COVID-19 (Health Imaging August 18, 2020)

“Nearly half of breast cancer survivors in the U.S. experienced care disruptions during the beginnings of the pandemic, according to new research, exposing dangerous cracks in the nation’s healthcare system.

A group from the University of Illinois at Chicago surveyed more than 600 women for their study, published recently in Breast Cancer Research and Treatment. About 44% said they experienced delays in care, with follow-up appointments and diagnostic imaging two of the leading types of postponements.

“Overall, we see that there is a serious gap in disaster preparedness when it comes to providing critical and often time-sensitive care for breast cancer patients,” Elizabeth Papautsky, PhD, assistant professor of biomedical and health information sciences at the UIC College of Applied Health Sciences, said Tuesday.”

(#256) Diagnostic imaging serves no purpose in assessing breast pain, internal medicine docs stress (Radiology Business August 17, 2020)

“Diagnostic imaging, and particularly MRI, serves no purpose in assessing patients’ breast pain, and physicians should largely discontinue the practice.

That’s according to a group of three internists with the University of Texas Southwestern Medical Center, in Dallas. Writing Monday in JAMA Internal Medicine, the group highlighted the case of a 36-year-old woman who presented with three months of discomfort and no personal or family history of cancer.

Primary care ended up ordering a diagnostic mammogram and later breast MRI that produced little to no benefit to the patient.”

(#255) ‘Cause for concern’: Unread second opinion reports cost one radiology department tens of thousands (Health Imaging August 12, 2020)

“Second opinion radiology reports often improve diagnostic interpretations and patient care but, when they aren’t read, can cost imaging departments tens of thousands in wasted resources.

In fact, one tertiary care center in the Netherlands found these unread reports resulted in more than $63,000 in losses, along with upwards of 130 hours in wasted rad interpretation time over one year. And authors of an Aug. 12 study believe nationwide figures would “substantially” raise those totals.

Co-author Sabine A. Heinz, and colleagues at University Medical Center Groningen’s Department of Radiology believe the problem can be remedied, but not until it is carefully analyzed.”

(#254) Automated CO-RADS algorithm spots COVID-19 patients, may relieve overworked radiologists (Health Imaging August 3, 2020)

“Hospitals in many states are reporting surging COVID-19 numbers, pushing some radiology departments to maximum capacity. But experts believe their new artificial intelligence-based reporting algorithm can offer much-needed relief.

Physicians from the Netherlands introduced their COVID-19 Reporting and Data System, known as CO-RADS, back in April. They proved the tool accurately offers clinicians a standardized process for assessing pulmonary involvement in CT scans.

And in a new study published July 30 in Radiology, experts from the same Dutch institution developed an artificial intelligence-based CO-RADS system, showing this method can identify which patients may have the disease based on their chest CT scans.”

(#253) MRI Screening: A Cost-Effective Strategy for Women with Breast Cancer Family History (Diagnostic Imaging August 1, 2020)

“For women of a certain age who have a family history of breast cancer, MRI scans can be a cost-effective screening method, according to recently published research.

In a study published in JAMA Oncology, investigators from the Netherlands determined that using MRI to screen women ages 35 to 60 who have at least a 20-percent familial risk of breast cancer is a financially sound identification method. They recommended screening every 18 months.

The team, led by H. Amarens Geuzinge, MSc, from the department of public health at Erasmus University Medical Center in Rotterdam, reached their determinations by using a simulator that estimated the cost and lives saved across a population of 10 million Dutch women.”

(#252) Making Mammography Recall Letters Easier-to-Understand Brings More Women Back for Follow-Up (Diagnostic Imaging July 31, 2020)

“Making it easier for patients to understand mammography recall letters can significantly improve how many women return in a timely manner for follow-up imaging.

These letters play a critical role in prompting many women to return for the supplemental breast imaging they need when their initial screenings reveal abnormal findings. However, in many instances, the letters contain confusing or unclear language.

To improve patient response to these communications, in 2019, investigators from Johns Hopkins Medicine revised the letter it sends to women who have suspicious findings. As a result, the team, led by Emily Ambinder, M.D., assistant professor of radiology and radiological sciences, determined that, not only did more patients understand the letters, but there was also a nearly two-fold increase in the likelihood they would participate in follow-up imaging.”

(#251) DBT doesn’t benefit subset of women facing higher breast cancer risk, poorest mammography outcomes (Health Imaging July 28, 2020)

“For most women, digital breast tomosynthesis is better than digital mammography at detecting cancer and reducing recall visits. New research, however, has pinpointed a subset of women who don’t experience these typical benefits.

The investigation, published Tuesday in JAMA Network Open, included more than 1.5 million breast exams. And while women with dense breasts largely saw a boost in cancer detection with DBT, also known as 3D mammography, a small percentage of higher-risk patients did not.

“DBT is improving screening outcomes for the vast majority of women getting screening mammography,” Kathryn Lowry, MD, assistant professor of radiology at the University of Washington School of Medicine in Seattle, said in a statement. “Unfortunately, it does not seem to benefit the 10% of women who have extremely dense breasts and who already experience the poorest of mammography outcomes today.””

(#250) Experts introduce CO-RADS as standardized way to assess CT imaging of COVID-19 patients (Radiology Business April 28, 2020)

“Across the globe, radiologists are grappling with conflicting and constantly evolving information as they attempt to assess and diagnose cases of COVID-19. A brand-new reporting system, however, may provide clarity in this confusion.

Imaging experts from the Netherlands recently unveiled their COVID-19 Reporting and Data System, or CO-RADS for short. The tool is based on previous efforts at standardization—such as BI-RADS in breast imaging—offering physicians an established process of assessing pulmonary involvement in CT scans.

CO-RADS ranks such findings on a scale of 1 (very low) to 5 (very high) and has logged solid results thus far, experts from the Dutch Radiological Society reported Monday, April 27.”

(#249) Experts pinpoint low-dose CT lung cancer screening fixes: ‘Radiologists must be creative and proactive’ (Radiology Business July 16, 2020)

“Low-dose lung cancer screening has been a hot topic in the news lately, with U.S. lawmakers recently pushing for greater efforts to expand use of this lifesaving clinical tool. Radiology researchers, meanwhile, have pinpointed predictors that patients will receive and stick with their cancer screening plan.

Just this week, the House Appropriations Committee advanced a 2021 spending bill for Health and Human Services that specifically calls out ongoing struggles with early detection.

“The committee remains concerned about the high morbidity and mortality of lung cancer,” lawmakers noted in the 384-page appropriations bill. “Early detection and treatment of lung cancer translates into higher survival rates, but only 16 percent of lung cancer cases are diagnosed early when the disease is most treatable,” lawmakers added, urging the Centers for Disease Control and Prevention to bolster promotion of such screenings as part of its anti-tobacco campaigns.”

(#248) USPSTF expands CT lung cancer screening guidelines to include more high-risk individuals (Health Imaging July 8, 2020)

“The U.S. Preventative Services Task Force on Tuesday proposed expanding recommendations that would significantly increase the number of Americans eligible for CT lung cancer screening, including more African Americans and women.

In the new draft statement, USPSTF calls for lowering the starting age of annual low-dose CT screening for smokers—who have a 20-pack-year smoking history or who have quit within the last 15 years—from age 55 down to 50. Previously, the task force recommended screening in those with a 30-pack-year history.

The new guidelines will be particularly helpful for spotting cancer in African Americans and women. Both groups tend to smoke fewer cigarettes than white men, with data showing Black individuals face a higher risk of lung cancer than white people.”

(#247) Incidental COVID-19 spotted on breast MR imaging, providing warning to radiologists (Radiology Business July 23, 2020)

“As radiologists tackle the massive backlog of breast imaging and other studies put on hold during the pandemic, researchers are warning them to be on the lookout for incidental COVID-19 cases.

U.K. imaging experts recently detailed these concerns in a new study, set to be published in the September issue of Radiology Case Reports. The narrow field of breast MR, in particular, includes the lungs and bony structures that must be assessed for any incidental mammary findings, noted lead author Adam Brown and colleagues.

“During the current pandemic special attention should be paid when analyzing any imaging which visualizes the lungs,” Brown and colleagues wrote. “Examples of this include breast MR, trauma imaging of the shoulder and abdominal CT or MR which includes the lung bases.””

(#246) Eating chocolate linked to healthier blood vessels, lower risk of CAD (Cardiovascular Business July 23, 2020)

“Eating chocolate—in moderation, of course—is associated with a reduced risk of coronary artery disease (CAD), according to new findings published in the European Journal of Preventive Cardiology.

“In the past, clinical studies have shown that chocolate is beneficial for both blood pressure and the lining of blood vessels,” lead author Chayakrit Krittanawong, MD, a cardiologist at the Baylor College of Medicine, said in a statement. “I wanted to see if it affects the blood vessels supplying the heart or not. And if it does, is it beneficial or harmful?”

Krittanawong and colleagues explored data from six different studies, good for a grand total of more than 336,000 patients. Eating chocolate more than once a week was specifically connected to an 8% decrease in a person’s risk of CAD. In particular, it appears that chocolate works wonders for the health of coronary arteries.”

(#245) New Genetic Score Helps Screen for Patients’ Risk of Fracture from Osteoporosis (Clinical OMICs July 23, 2020)

“An international team of researchers has developed a new genetic risk score that could dramatically improve screening for osteoporosis. The team, which includes scientists from the University of Sheffield, developed the gSOS scoring system based on clinical information from more than 340,000 individuals who donated health data to the UK Biobank. The study was published in the journal PLOS Medicine

“As the population ages, the urgency of improving preventive measures becomes all the more intense,” says Eugene McCloskey, professor in Adult Bone Diseases at the University of Sheffield. He adds that, “Bone strength, a key component underlying fracture risk, is highly heritable (up to 85 per cent determined by our genes), and is therefore a strong candidate for assessment through genetic screening.””

(#244) ACR: Congress should include delay of ‘controversial’ USPSTF breast cancer screening in final funding bill (Health Imaging July 9, 2020)

“The American College of Radiology is urging Congress to pass a draft bill that includes a delay of U.S. Preventive Services Task Force breast cancer screening mammography recommendations.

A House subcommittee recently approved the fiscal year 2021 funding bill by a nine to six vote. It extends the current delay in instituting 2009 USPSTF screening guidelines through 2025. The “controversial” guidance pushes for biennial screening beginning at age 50; language in the current bill retains insurance coverage of annual mammograms for women 40 years and older.

“ACR supports the extension of the moratorium against the most recent USPSTF breast cancer screening recommendations,” Dana Smetherman, MD, chair of the ACR Breast Imaging Commission, said in a statement provided to Health Imaging. “The ACR, Society of Breast Imaging, American Cancer Society and even the USPSTF all agree that the most lives are saved when women begin screening at age 40 and are screened annually.””

(#243) Pre-Operative Breast MRI Diagnoses More Cancers in Women with DCIS (Diagnostic Imaging July 9, 2020)

“Women who have ductal carcinoma in situ (DCIS) can benefit from undergoing pre-operative breast MRI, new research has revealed. These scans pinpoint 11 percent more cancers, indicating the images could augment surgical planning and lead to better outcomes.

In a study published recently in the European Journal of Radiology, investigators from Massachusetts General Hospital determined incorporating pre-operative breast MRI can positively impact the surgical management of women with DCIS.”

(#242) Updated USPSTF Lung Cancer Screening Guidelines (ITN Online July 8, 2020)

“Changes outlined in new draft U.S. Preventive Services Task Force (USPSTF) lung cancer screening recommendations will greatly increase the number of Americans eligible for screening and help medical providers save thousands more lives each year, according to a new statement issued by the American College of Radiology (ACR).

The American College of Radiology strongly supports the USPSTF proposal to lower the starting age for screening from 55 to 50 and the smoking history requirements from 30 pack-years to 20 pack-years. The ACR encourages efforts to expand screening — particularly among minorities and women. The College will provide further input to the USPSTF in the coming weeks.”

(#241) Interval breast cancers’ aggressiveness may stem from unique biology, JAMA study finds (Radiology Business June 30, 2020)

“Breast cancer detected within one year after previous negative mammography studies appear to be more destructive in nature and it may not be attributed solely to the delayed diagnosis.

Rather, such “interval breast cancers,” as they’re commonly called, may have a uniquely aggressive biology that could require additional actions from radiologists, experts wrote Tuesday in JAMA Network Open. Scientists from several institutions led by Oregon State University reached their conclusions by analyzing data from more than 3,000 patients included in the Women’s Health Initiative.

Veronica Irvin, PhD, and colleagues determined that those with interval breast cancer detected within one year of a negative mammogram had measurably worse outcomes compared to those detected through regular screenings. That included larger tumors, more lymph node involvement, and higher breast cancer-related mortality.”

(#240) The messages hospital marketing execs are using to bring patients back (Becker’s Health IT June 25, 2020)

“Hospital and health system marketing executives nationwide are taking on the tough task of assuring patients it is safe and necessary to maintain their physical health and return to healthcare facilities — even amid a pandemic.

Many patients still feel anxiety surrounding virus contraction and are delaying care, so hospital marketing leads must be strategic when communicating how their facilities are keeping patients protected during the pandemic.

Here, seven healthcare marketing executives share what they believe is the most effective message to encourage patients to return for medical care.”

(#239) More than 20% of patients have caught errors in their radiology report or other doc notes (Radiology Business June 10, 2020)

“About 1 in 5 patients said they have caught an error in their radiology report or other physicians’ notes, with 40% perceiving the mistake as “serious” in nature.

That’s according to a new survey of almost 30,000 patients, led by Harvard Medical School and published Tuesday in JAMA Network Open. Such serious errors, the authors noted, included incorrect medical histories or medication regimens and notes taken on the wrong subject.

“Patients also reported mistakes in radiology results or practitioner summaries of radiology reports that made it difficult to determine whether there was clinical improvement or deterioration,” wrote lead author Sigall Bell, MD, with Harvard and its affiliated Beth Israel Deaconess Medical Center in Boston, and colleagues. In one such instance, an MRI report used both centimeters and millimeters as units of measurement, creating “ambiguity” for the reader.”

(#238) Law change would require health insurers to cover breast MRI, ultrasound for high-risk patients  (Radiology Business June 9, 2020)

“Pennsylvania has advanced legislation that would require health insurers to cover supplemental MR and ultrasound imaging of women at high risk of breast cancer.

The state’s House Insurance Committee unanimously approved the legislation recently, setting up consideration by the full body. State Sen. Bob Mensch, R-Montgomery County, sponsored the bill and praised its advancement in late May. It’s been in the works now for nearly a decade, he noted.

“When I first introduced the bill in 2011, I never thought I would still be working on it all these years later,” he said in a statement.  “While the bill has morphed and changed over the past years, I’m confident the version we have now ready to pass the House will help countless women in Pennsylvania.”

(#237) Experts introduce CO-RADS as standardized way to assess CT imaging of COVID-19 patients (Radiology Business April 28, 2020)

“Across the globe, radiologists are grappling with conflicting and constantly evolving information as they attempt to assess and diagnose cases of COVID-19. A brand-new reporting system, however, may provide clarity in this confusion.

Imaging experts from the Netherlands recently unveiled their COVID-19 Reporting and Data System, or CO-RADS for short. The tool is based on previous efforts at standardization—such as BI-RADS in breast imaging—offering physicians an established process of assessing pulmonary involvement in CT scans.”

(#236) ACR issues 7-step plan to get radiology practices back to business (Radiology Business May 6, 2020)

“The American College of Radiology issued a seven-step plan on Wednesday to help imaging practices across the country begin to resume normal operations after weeks of disruption.

More than a dozen doctors from all corners of the country contributed to the document, which represents the official position of the college. Given the many intricacies in each locality, ACR admitted there is no “single prescriptive strategy.” However, all radiology providers should carefully weigh the costs and benefits of resuming care in this new normal.

“If the risk of illness or death to a healthcare worker or patient from healthcare-acquired COVID-19 is greater than the risk of illness or death from delaying radiology care, the care should be delayed,” the team of experts, led by Michigan Medicine radiologist Matthew Davenport, wrote May 6 in JACR. “However, if the opposite is true, the radiology care should proceed in a timely fashion.””

(#235) Many patients have COVID-19 lung abnormalities at discharge; follow-up imaging may be necessary (Health Imaging March 20, 2020)

“An overwhelming majority of patients with COVID-19 had mild to significant lung abnormalities on their chest CT scans when they were discharged from the hospital, according to a new study. Experts believe these groups may need closer follow-up observation.

That was a primary takeaway from a longitudinal analysis of 90 patients with coronavirus-related pneumonia, published March 19 in Radiology. After analyzing hundreds of images, the researchers were able to pinpoint when CT abnormalities peaked and the changes in these patterns over time.

First author Yuhui Wang, with Union Hospital’s radiology department in Wuhan, Hubei, China, and colleagues believes knowledge of these transformations can go a long way in the battle to save lives.”


(#234) Mammography Offers No Additional Benefit to Women Over 75 (Diagnostic Imaging February 26, 2020)

“Women over age 75 do not experience a clear benefit if they continue receiving screening mammograms, new research has determined.

Investigators from the Harvard T.H. Chan School of Public Health, Massachusetts General Hospital, and RTI Health Solutions, revealed results in the Annals of Internal Medicine this week that showed that, even though there is no clear age at which women should stop getting mammograms, there’s no additional survival benefit after age 75. Currently more than 50 percent of women over age 75 get mammograms.”


(#233) Abbreviated MRI Outperforms 3D Mammography with Dense Breasts (Diagnostic Imaging February 25, 2020)

“Women who have dense breasts and an average risk for breast cancer have a better chance of receiving an accurate breast cancer screening with abbreviated MRI than they do with 3D mammography.

New research published today in Journal of the American Medical Association, conducted by the ECOG-ACRIN Cancer Research Group, reveals the shorter exam was more than twice as effective in pinpointing malignant findings than digital breast tomosynthesis, contributing additional data to the push for adding abbreviated MRI to the available cadre of screening tools.”

(#232) Stick to breast imaging evidence, radiologists implore: ‘Lives are at stake and compromise is unethical’ (Radiology Business February 28, 2020)

“A group of radiologists issued an impassioned plea recently, urging their peers to stick to the evidence when screening women for breast cancer.

The Feb. 26 Journal of the American College of Radiology commentary implored docs to begin mammography testing of women at age 40, and at annual intervals. Recommendations from healthcare administrators or other nonradiologists that say otherwise should not dictate women’s care, wrote lead author Harvard Medical School’s Daniel Kopans, MD.

“We understand administrative pressure and the rights of each of you as individuals to have your own opinions, but this is not something that is subject to opinion,” wrote Kopans, who specializes in mammography…””

(#231) Radiologists are wasting too much time communicating routine results over the phone (Radiology Business February 18, 2020)

“In the emergency department, a simple phone call from radiologist to referring physician to convey abnormal test results quickly can prove pivotal to saving a patient’s life. However, if imaging findings are routine, that same phone call may be a waste of time that pulls important resources away from individuals who urgently need them.

That’s one of the key takeaways from a new analysis of radiologist communication in one large ED, published Monday in the Canadian Association of Radiologists Journal. Analyzing all such communication over a one-week period, researchers found that radiologists spent about 10% of their workday communicating results over the phone ahead of delivery of their final report.”

(#230) Inconsistent AI: Deep learning models for breast cancer fail to deliver after closer inspection (AI in Healthcare February 18, 2020)

“Numerous deep learning models can detect and classify imaging findings with a performance that rivals human radiologists. However, according to a new study published in the Journal of the American College of Radiology, many of these AI models aren’t nearly as impressive when applied to external data sets.

“This potential performance uncertainty raises the concern of model generalization and validation, which needs to be addressed before the models are rushed to real-world clinical practice,” wrote first author Xiaoqin Wang, MD, University of Kentucky in Lexington, and colleagues.”

(#229) Radiology reports must evolve to serve patient audience, expert asserts (Radiology Business January 14, 2020)

“The Centers for Medicare and Medicaid Services (CMS) announced that it will begin covering FDA approved/cleared diagnostic tests that use next generation sequencing (NGS) to detect inherited ovarian and breast cancer.

“Today’s savvy healthcare consumer wants to receive an easy-to-digest copy of their radiology report in a timely manner, and the burden is squarely on radiologists to figure out how to make that a reality.

Vivek Kalia, MD, a musculoskeletal imaging expert with Michigan Medicine, recently made this call to action to his peers in a new Academic Radiology editorial. He believes the specialty is entering a “new era” where readers’ duties extend well-beyond that final document detailing their findings.”

(#228) CMS to Cover NGS Laboratory Tests for Breast, Ovarian Cancer (FDANews January 28, 2020)

“The Centers for Medicare and Medicaid Services (CMS) announced that it will begin covering FDA approved/cleared diagnostic tests that use next generation sequencing (NGS) to detect inherited ovarian and breast cancer.

“NGS tests provide the most comprehensive genetic analysis of a patient’s cancer because they enable simultaneous detection of multiple types of genetic alterations,” said CMS Administrator Seema Verma.

The NGS diagnostics provide clinical information that can help physicians develop a personalized cancer treatment plan for each patient.”

(#227) Radiologists could double dip during mammography, further population health goals (Radiology Business January 10, 2020)

“Screening mammography presents a perfect opportunity for radiologists to double dip and also address smoking cessation and lung cancer, experts believe.

Investigators with Massachusetts General Hospital recently tested out this theory at a health center affiliated with the Boston-based institution. Their findings, published Jan. 10 in the Journal of the American College of Radiology, support the idea that, with simple changes, radiologists can add value to their practices while also furthering hospitals’ big-picture wellness goals.

“Screening mammography is an ongoing healthcare touch point for millions of women nationwide. As such, screening mammography visits represent opportunities for radiology practices to improve population health in ways beyond providing breast cancer screening,” wrote Gary Wang, MD, PhD, with the Department of Radiology at Mass General.”

(#226) An instant 2nd opinion: Google’s DeepMind AI bests doctors at breast cancer screening (Fierce BioTech January 2, 2020)

“Google’s DeepMind team showed that it can outperform trained radiologists in spotting cases of breast cancer, and that its artificial intelligence is capable of providing an independent, automated and immediate second opinion.

By using programs trained on 2D and 3D mammography images from nearly 30,000 women in the U.S. and the U.K., DeepMind’s system was able to identify those that had their cancer confirmed within the following year via a tissue biopsy or subsequent X-rays.

Among patients from the U.S., the AI cut the number of people incorrectly referred for further screening with a false-positive result by 5.7%—while also detecting 9.4% of potentially missed breast cancer cases. Published in Nature, the study said it surpassed the work of six independent physicians.”

(#225) New Drug from Under-the-Radar Biotech Company Successfully Tricking the Body’s Immune System into Fighting Cancer Cells (USA News Group October 6, 2019)

“Amid the fierce war being waged against cancer by drug developers, there’s a biotech segment growing at lightning speed (+20% CAGR)… they’re front and center in the oncology space.

That segment is known as checkpoint blockade immunotherapy (or immune checkpoint inhibitors). You can be forgiven if you’re unfamiliar with the sector, but we urge you to read on to learn more about this exciting opportunity.

Projected to reach more than $56.5 billion by 2025, the global immune checkpoint inhibitors market is growing at CAGR of 20.1% — it’s the fastest growing segment of immuno-oncology.”

(#224) Bayer earns FDA clearance for contrast-enhanced mammography injection system (Radiology Business December 20, 2019)

“The Food and Drug and Administration has authorized the expanded use of Bayer’s latest injection system to begin delivering agents used in contrast-enhanced mammography, the manufacturer announced Thursday, Dec. 19.

Company officials noted that the MEDRAD Stellant FLEX can now assist radiologists in delivering iodine intravenously, making it easier to spot breast abnormalities once unseen through traditional mammography.

“This FDA clearance underscores Bayer’s continued commitment to women’s health, and we are pleased to now support contrast-enhanced mammography as another alternative screening option for women,” Dennis Durmis, head of Bayer Radiology’s Americas region, said in an announcement.”

(#223) Artificial intelligence bolsters breast cancer risk prediction (Radiology Business December 17, 2019)

“Swedish scientists have developed a sophisticated new artificial intelligence model that may greatly improve radiologists’ ability to predict breast cancer risk when compared to traditional methods.

This deep neural network was able to extract vast amounts of data from images, and deduce a higher cancer risk association when compared to even the best mammographic breast density model. It produced a lower false negative rate, too, and is only expected to grow smarter as it’s fed more images, researchers noted in their study, published Tuesday, Dec. 17, in Radiology.

“The deep neural network overall was better than density-based models,” lead author Karin Dembrower, MD, a breast radiologist and PhD candidate with the Karolinska Institute in Stockholm, Sweden, said in a statement. “And it did not have the same bias as the density-based model. Its predictive accuracy was not negatively affected by more aggressive cancer subtypes.””

(#222) Breast Cancer Cells Use Unexpected Mechanism to Suck Up Fats (GenEngNews December 16, 2019)

“The link between high-fat diets, obesity, and cancer has grown stronger over the past several years. Yet, the underlying molecular mechanisms have been slow to surface. Now, investigators from Dartmouth College and the Dartmouth-Hitchcock Norris Cotton Cancer Center set out to understand how fat from the diet might influence breast cancer (BC) cells. Interestingly, the researchers found that in addition to making new fat to fuel proliferation, breast cancer cells can take up large quantities of fat derived from the lipid-rich particles that circulate in the bloodstream.”

(#221) 6 takeaways for radiologists from the past decade of breast cancer-related malpractice lawsuits (Health Imaging December 12, 2019)

“Mammography screening for breast cancer has advanced rapidly, helping lower mortality rates by nearly 40% since its widespread adoption. Medical malpractice fears have unfortunately increased in the process.

More than 60% of radiologists interpret breast imaging studies, according to figures published Dec. 11 in Clinical Imaging. And paired with the fact that there is a nearly 50% chance a radiologist will be tangled up in a malpractice claim by the time they turn 60, many are thinking twice before interpreting breast imaging exams.”

(#220) 4 things radiologists should know about Pennsylvania’s patient notification law (Health Imaging October 3, 2019)

“Pennsylvania (PA) Act 112, requires imaging facilities in the state to notify patients of abnormal imaging results. Authors of a Sept. 28 case study published in the Journal of the American College of Radiology examined what this law does and how it might impact patients and radiologists.

The “Patient Test Result Information Act” became law on Oct. 24, 2018, and defines abnormal findings as a “finding that would cause a reasonably prudent person to seek additional or follow-up medical care within 3 months,” wrote Gregory S. Mittl, MD, MBA, with Hospital of the University of Pennsylvania’s department of radiology in Philadelphia, and colleagues.

Below are important facts radiologists should know about PA Act 112…”

(#219) Permanent hair dyes may increase breast cancer risk by as much as 60% for some women (Radiology Business December 5, 2019)

“Using permanent hair dyes or chemical straighteners may increase some women’s chance of developing breast cancer by upward of 60%, according to a new study.

Researchers with the National Institute of Environmental Health Sciences (NIEHS) recently made that discovery by analyzing data from almost 47,000 individuals. Their results—published Wednesday, Dec. 4, in the International Journal of Cancer—may add some credence to a long-held theory.

“Researchers have been studying the possible link between hair dye and cancer for a long time, but results have been inconsistent,” author Alexandra White, PhD, head of the NIEHS Environment and Cancer Epidemiology Group, said in a statement. “In our study, we see a higher breast cancer risk associated with hair dye use, and the effect is stronger in African American women, particularly those who are frequent users.””

(#218) RSNA 2019: A revised perspective is central to a new era of patient-centered radiology (Health Imaging December 1, 2019)

“Radiology has been at the forefront of many technological advances in medicine, but imaging experts may need to adjust their perspective if they want to continue leading the field.

That was the message delivered during Sunday’s presidential address at the Radiological Society of North America 2019 annual meeting. RSNA President Valerie P. Jackson, MD, urged radiologists to look within themselves, step out of the reading room and connect with others in order to move toward the “long desired goal” of more direct patient connection.

The timing is particularly important, said Jackson, who is also executive director of the American Board of Radiology, given the ballooning number of burned out physicians, an ever-increasing focus on value-based care, and the potential for AI to assume time-consuming tasks and afford radiologists more time to interact with patients.”

(#217) Congress introduces bill to cover DBT exams for TRICARE beneficiaries (Health Imaging November 27, 2019)

“A bipartisan group of lawmakers recently introduced a bill to cover digital breast tomosynthesis (DBT) screening exams for service members and their families.

Sen. Martha McSally (R-AZ) introduced the “Better and Robust Screening Today Act,” which would mandate the Department of Defense to cover DBT screenings, a modality the lawmakers say is the best tool available for detecting breast cancer.

McSally, a veteran herself, said that while the Department of Veteran Affairs does cover DBT, under TRICARE, the screening is only paid for as a secondary option.

“Service members and their families sacrifice so much and deserve the best healthcare and technology available,” McSally said in a statement. “There is simply no good reason to deny DBT screening, the latest breast cancer imaging technology, to Tricare patients.””

(#216) Opinion: Navigating the Complexities of Value-Based Cancer Care (Managed Healthcare Exec. November 9, 2019)

“Cancer is among the most frightening diagnoses for patients to receive.

It is a daunting challenge for oncology treatment specialists, and a persistent challenge for policy makers, payers, and other parties charged with ensuring that high-quality, evidence-based, cost-effective care is delivered consistently for all patients.

In addition to the physical manifestations of oncologic disease and the often very difficult treatment side-effects, many patients experience significant financial distress as a result of their diagnosis and treatment.

Patients are also often left to navigate a complex and unclear labyrinth of healthcare services on their own during a period of intense physical and emotional vulnerability—the disjointed care that is one of the most unfortunate results of the prevailing fee for service payment methodology.”

(#215) Survey: Breast density awareness on the rise, though notable disparities still exist (Radiology Business November 20, 2019)

“Awareness of breast density and its relation to cancer has grown in the United States over the past five years. However, certain minority populations are still lagging behind their peers when it comes to this important clinical marker.

Those are some of the key takeaways from a new Mayo Clinic survey of almost 3,000 women, representative of the entire U.S. population. Comparing public sentiment to a previous survey conducted five years prior, Mayo researchers found that about 65.8% of women were aware of breast density’s importance in 2017, compared to 57.5% in the previous survey.

However, race, income and education “significantly” impacted this awareness negatively, signaling the need for better outreach to less-served patient segments, according to the study, published Tuesday, Nov. 19, in the Journal of the American College of Radiology.”

(#214) Ultrasound-visible clips prove practical, cost-effective for guiding breast surgery (Radiology Business November 20, 2019)

“Biopsy clips can outperform conventional wires for localizing breast cancers, as the former may boost utilization of ultrasound guidance for tumor resection, in the process minimizing patient discomfort while helping control costs.

That’s according to researchers at the University of Vermont who compared localization techniques. Their findings were published online Nov. 18 in the Journal of Ultrasound in Medicine.

Senior study author Michelle Sowden, DO, and colleagues analyzed data on 2,209 patients who had a breast biopsy at their institution over a three-year period ending in 2016.”

(#213) American Lung Association finds ‘dramatic’ increase in lung cancer survival rates, with radiologists playing a key role (Radiology Business November 14, 2019)

“Receiving that initial lung cancer diagnosis is not the death sentence that it used to be for some Americans, with more surviving the disease than ever before.

The American Lung Association made that assertion in its newest State of Lung Cancer report, released on Wednesday, Nov. 14. Almost 22% of individuals diagnosed with lung cancer are still fighting five years later, up from 17.2% just a decade ago. That’s a 26% increase according to the ALA, one that’s partly attributable to better screening using low-dose CT scans to catch the cancer early on.

“Lung cancer has touched far too many lives, and this year’s ‘State of Lung Cancer’ report offers tremendous hope and reaffirms our belief in the lifesaving potential of screening and cancer research to turn the tide against this disease,” ALA National President and CEO, Harold Wimmer said in a statement.”

(#212) 3D-Printed Breast Implants Could Be the Next Big Thing in Plastic Surgery (MD+DI November 12, 2019)

“Two German companies have paired up on the development of a technology that could disrupt the breast implant market.

BellaSeno will use Evonik’s Resomer bioresorbable polymer in its Senella breast scaffolds with a proprietary additive manufacturing process that avoids the use of silicone implants, some of which have raised major safety concerns.

BellaSeno plans to begin first-in-human clinical trials of the Senella scaffolds with Resomer in Germany this quarter. Evonik has agreed to supply its Resomer polymer for clinical and commercial use. The scaffolds are designed to guide the growth of natural tissue using the patient’s own body fat harvested via liposuction.”

(#211) Hologic Combines AI with Breast Cancer Imaging (MD+DI November 12, 2019)

“Hologic is bringing artificial intelligence to breast cancer imaging with its latest product. The Marlborough, MA-based company has won a nod for the 3DQuorum Imaging Technology, powered by Genius AI.

3DQuorum technology uses Genius AI-powered analytics to uniquely reconstruct high-resolution 3D data to produce 6 mm “SmartSlices.” These analytics identify clinically relevant regions of interest and preserve important features during the reconstruction of the SmartSlices.

This helps to expedite read time by reducing the number of images for radiologists to review, without compromising image quality, sensitivity or accuracy. With 3DQuorum technology, the number of 3D images to review is reduced by two-thirds, saving an average of one hour per eight hours of daily image interpretation time.”

(#210) Just 10% of patients with access check out their medical information (HealthExec November 8, 2019)

“While more policies are pushing toward increasing patient access to electronic medical records, few patients are actually using the opportunity to check out their own information, according to a study published in Health Affairs.

Many new CMS initiatives and Trump administration executive orders are focused on improving transparency for patients to find higher quality care for a better price. CMS and the Office of the National Coordinator for Health Information Technology (ONC) is working to improve interoperability across the healthcare system and would require all healthcare providers to offer electronic records available to patients for free under a proposed rule. The proposal has seen pushback from the industry.

Some evidence has shown that when patients use their health information, they are more engaged and see improved satisfaction and convenience. But these policies hinge on the involvement of the patient actually accessing their health information.”

(#209) AI helps predict when DCIS will progress to invasive breast cancer (AI in Healthcare October 29, 2019)

“Researchers have uncovered a new way to determine when ductal carcinoma in situ (DCIS) is most likely to progress to a more invasive cancer, according to new findings published in Breast Cancer Research.

The team used an advanced computer program to examine lumpectomy tissue samples from 62 different patients diagnosed with DCIS. This helped them focus on certain features of the tissue samples—tumor size and orientation, to be specific—that seemed to suggest a higher likelihood of DCIS progression. Those features were then combined with machine learning to establish detailed risk categories.

The researchers hope their work can limit the amount of radiation patients are exposed to when receiving care. It could also keep patients from undergoing the Oncotype DX genetic test when not necessary.”

(#208) Smaller, lighter, cheaper: A serial entrepreneur wants his portable MRI to transform medicine (Stat News October 25, 2019)

“GUILFORD, Conn. — In a nondescript building in this seaside town sits a prototype that could change the way that doctors use magnetic resonance imaging.

Usually an MRI machine requires a giant, powerful magnet and must be encased in its own copper-shielded room. It is why the behemoths cost hundreds of thousands or even millions of dollars. But this device, from a startup called Hyperfine, is about the size of a luggage cart. It could be wheeled from one bed to another.”

(#207) What’s New in Mammography (Diagnostic Imaging October 22, 2019)

“For decades, mammography has stood alone as the gold standard for breast cancer screening and detection. But, being the go-to strategy for identifying the early-stage or advanced cancers isn’t enough. Work has continued to not only augment the efficacy of mammography, but to also increase its use and reach.

Industry-wide, there are efforts underway to design and implement new technologies and strategies for mammography. And, research is also revealing new ways for the modality to make an impact on saving lives.”

(#206) Cancer history, costs inhibit follow-up compliance among BI-RADS 3 patients (Health Imaging October 10, 2019)

“There is no shortage of research investigating the effectiveness of the Breast Imaging Reporting and Data System (BI-RADS) category 3 in mammography, but what’s less understood is why some women complete follow-up recommendations while many do not.

A BI-RADS 3 designation indicates there is between a 0% and 2% chance of cancer, for which physicians recommend six-month follow-up. Authors of an Oct. 8 study published in the Journal of the American College of Radiology found while a majority of patients completed follow-up, only slightly more than half did so in the appropriate time frame.”

(#205) Massive marketing muscle pushes 3D mammograms, despite no evidence they save more lives, investigation shows (USA Today October 18, 2019)

“When Dr. Worta McCaskill-Stevens made an appointment for a mammogram last year, she expected a simple breast cancer screening – not a heavy-handed sales pitch.

A receptionist asked if she wanted a free upgrade to a “3D mammogram,” or tomosynthesis.

“She said there’s a new approach and it’s much better, and it finds all cancer,” said McCaskill-Stevens, who declined the offer.

A short time later, a technician asked again: Was the patient sure she didn’t want 3D?”

(#204) Fewer men get breast cancer—but more cases are fatal compared to women (Health Imaging October 15, 2019)

“Men make up nearly 1% of all breast cancer cases in the U.S., but their mortality rate is drastically higher compared to women diagnosed with the disease.

STAT recently reported on a study that analyzed mortality data from more than 1.8 million female patients and 16,025 men who were diagnosed with breast cancer. Men had a 19% higher mortality rate compared to women, and the lack of male representation in the study further highlighted the gender disparity associated with the disease, according to STAT reporter Alexander Spinelli.”

(#203) Why women are skipping their follow-up breast cancer MRI (Radiology Business October 11, 2019)

“Women initially deemed to have a less than 2% chance of developing breast cancer often skip the recommended follow-up MRI six months later. Johns Hopkins researchers are attempting to understand why, and recently published some early insights into the issue.

They estimated that about 24% of patients categorized as a 3 in the Breast Imaging Reporting and Data System (BI-RADS) did not return for their re-examination. Factors fueling that failure included high out-of-pocket expenses and a lack of any past history of breast cancer in the family, according to the study, published Oct. 8 in the Journal of the American College of Radiology.”

(#202) Cancer history, costs inhibit follow-up compliance among BI-RADS 3 patients (Health Imaging October 10, 2019)

“There is no shortage of research investigating the effectiveness of the Breast Imaging Reporting and Data System (BI-RADS) category 3 in mammography, but what’s less understood is why some women complete follow-up recommendations while many do not.

A BI-RADS 3 designation indicates there is between a 0% and 2% chance of cancer, for which physicians recommend six-month follow-up. Authors of an Oct. 8 study published in the Journal of the American College of Radiology found while a majority of patients completed follow-up, only slightly more than half did so in the appropriate time frame.

The team from Johns Hopkins in Baltimore set out to understand why.”

(#201) What radiologists should know about vaping-related lung injuries (Health Imaging October 9, 2019)

“The CDC issued a health advisory on Aug. 30, warning of severe pulmonary diseases associated with e-cigarette use, including 215 reported cases and one confirmed death.

Since then, the New England Journal of Medicine published a Sept. 6 study linking a cluster of respiratory illness cases identified on CT scans to e-cigarette use. A group of U.S. researchers analyzed literature on the topic, summarizing imaging findings to help radiologists identify signs of vaping-related lung injuries. The results were published Oct. 8 in the American Journal of Roentgenology.”

(#200) Which breast cancer phenotypes have the greatest influence on MRI? (Health Imaging October 7, 2019)

“Breast cancer phenotype can influence MRI’s ability to evaluate the effectiveness of chemotherapy, according to a study published Oct. 4 in the European Journal of Radiology. But which specific tumor subtypes have the greatest impact on the modality’s performance?

“Achievement of pathologic complete response (pCR) after (neoadjuvant chemotherapy ) NAC is associated with better prognosis in breast cancer patients, especially when more aggressive subtypes are present,” wrote Erika M. S. Negrão, with Hospital de Câncer de Barretos in Brazil, and colleagues. “Breast MRI can accurately assess treatment response after NAC in most cases, however it is important to know when MRI may be less accurate.””

(#199) Physical Exam Not Augmented by Breast Ultrasound in Younger Women (Diagnostic Imaging October 2, 2019)

“Breast cancer awareness campaigns and revelations about the genetic links of the disease have elevated breast cancer concerns among women of all ages in the past 20 years. That increased anxiety often leads younger women—even those with no elevated risk factors who are considered too young for mammography—to discuss early screening efforts with their doctors.

According to National Cancer Institute statistics, this fear isn’t without some foundation. In the United States, roughly 12,150 women under age 40 and 26,393 women under age 45 will receive a breast cancer diagnosis each year. These diagnoses result in approximately 1,000 deaths annually.”

(#198) Breast Ultrasound Equally Beneficial After Mammography and Breast Tomosynthesis (Diagnostic Imaging October 2, 2019)

“When it comes to identifying breast cancer in women, mammography is still considered the gold standard screening option. In recent years, however, digital breast tomosynthesis has been gaining ground as a modality that can provide better detection for women with dense breasts.

Regardless of the method, radiologists frequently suggest additional breast ultrasound screening when results are unclear. And, new research, published in the American Journal of Roentgenology, reveals supplemental breast ultrasound provides the same level of additional cancer detection after digital breast tomosynthesis as it does after digital mammography.”

(#197) Study Finds Breast, Ovarian Cancer Gene Tests Cost-Effective for Unselected Breast Cancer Patients (Geonomeweb October 3, 2019)

“NEW YORK – Health systems in the UK and US could cost-effectively screen all women with breast cancer for risky germline changes in a handful of breast or ovarian cancer genes, according to a new economic modeling analysis, identifying at-risk individuals who could benefit from additional imaging tests and cancer-reducing interventions.”

(#196) Higher-dose statins raise risk for osteoporosis (Cardiovascular Business September 30, 2019)

“The higher the dosage of cholesterol-lowering statins, the greater a patient’s risk of developing osteoporosis, according to work published in the Annals of Rheumatic Diseases.

In their paper, Alexandra Kautzky-Willer, an expert in gender medicine and endocrinology and head of the Medical University of Vienna, and colleagues explained that statins—among the most widely prescribed drugs worldwide—effectively lower cholesterol and reduce the risk of CVD, but they also inhibit the synthesis of cholesterol, a critical building block for sex hormones like estradiol and testosterone.”

(#195) RSNA launches new publication focused on cancer imaging (Radiology Business September 27, 2019)

“The Radiological Society of North America announced Friday that it’s launching a new journal dedicated to imaging in oncology.

Radiology: Imaging Cancer is one of three new journals recently launched by the RSNA and will collect studies on clinical cancer studies across all disease types.

“We are delighted that RSNA has started this journal as a new venue for scientists and physicians to disseminate and learn the latest discoveries in cancer imaging,” editor Gary Luker, MD, associate chair for clinical research in the radiology department at Michigan Medicine, said in a statement.”

(#194) G1 shares data on significant increase in breast cancer survival (Fierce BioTech September 28, 2019)

“G1 Therapeutics has linked the addition of trilaciclib to chemotherapy to improved overall survival (OS) in triple-negative breast cancer (TNBC) patients. People who received the CDK4/6 inhibitor lived 20.1 months, on average, as compared to 12.6 months for their peers in the chemotherapy cohort.

Trilaciclib initially underwhelmed in TNBC. In December, G1 presented data (PDF) showing no difference in the number of patients experiencing myelosuppression events across the trilaciclib and control arms, denting a rationale for using the drug in TNBC.”

(#193) US yields similar cancer detection rates after digital mammography, DBT (Radiology Business September 26, 2019)

“Screening ultrasound (US) examinations after digital breast tomosynthesis (DBT) and after digital mammography (DM) result in comparable cancer detection rates, according to a new study published in the American Journal of Roentgenology.

DBT continues to gain popularity throughout the United States, but researchers are still learning more about its impact on patient care.

“Compared with DM, DBT improves detection of breast cancer in women with dense breasts,” wrote Elizabeth H. Dibble, MD, Rhode Island Hospital in Providence, and colleagues. “The value US screening adds in patients who have already undergone mammographic screening with DBT remains unclear.””

(#192) 3 reasons the mammography market may soon slow down (Radiology Business August 2, 2019)

“Growth in the mammography market may begin to slow down in the near future, according to a new analysis from Signify Research.

Author Imogen Fitt described mammography as the breast imaging industry’s “undisputed modality of choice,” but also noted that it could be in for a significant shift. And how did she come to that conclusion? In her analysis, Fitt provided three key reasons:

  1. DBT growth may have peaked

Digital breast tomosynthesis (DBT) adoption has provided the mammography market with a big boost, especially in the United States. But, as Fitt explained, “what goes up must eventually come down.”

“Despite recording an increase in the installed base of systems for 2018, vendors have reported that growth in the U.S. market has begun to slow,” she wrote. “As of June 2019, 61% of certified facilities possessed at least one DBT unit, and the market has now moved into late-stage adoption.””

(#191) What NLST data tells us about Lung-RADS (Radiology Business September 23, 2019)

“Subsolid pulmonary nodules classified as Lung Imaging Reporting and Data System (Lung-RADS) categories 2 and 3 may have a higher risk of malignancy than previously believed, according to new findings published in Radiology.

The study’s authors examined more than 400 subsolid nodules from the National Lung Screening Trial (NLST), remeasuring each nodule and looking at any subsequent follow-up imaging results. Overall, 304 nodules were classified as Lung-RADS category 2. The malignancy rate for those nodules was 3%, higher than the 1% reported as part of Lung-RADS.”

(#190) Can Bowel Cancer Screening Reduce Patient Death? (MD+DI September 20, 2019)

“A new study from the University of South Australia researchers found the number of people that die from bowel or colorectal cancer (CRC) would be much higher without pre-diagnostic colonoscopies. Now more than 700,000 people die from bowel cancer each year according to the university.

The researchers from the University’s Cancer Epidemiology and Population Health looked at data from 12,906 bowel cancer patients that indicate the fecal occult blood testing (FOBT) with a follow-up colonoscopy plays a key role in catching the disease early before symptoms appear.”

(#189) How to fix a big problem with state-mandated breast density notifications (Radiology Business September 19, 2019)

“State-mandated breast density notifications (BDNs) are too complex for all patients to understand, according to new findings published in the Journal of the American College of Radiology. Simplifying the language of BDNs could make a significant impact on patient care.

“To realize the full benefits and intent of BDNs, it is critical that women understand these state-mandated communications,” wrote Derek L. Nguyen, MD, Johns Hopkins Medicine in Baltimore, and colleagues. “Thus, a study to assess the impact of the language in these notifications is timely and relevant.””

(#188) Radiation After Immunotherapy Improves Progression-free Survival for Some Metastatic Lung Cancer Patients (Imaging Technology News September 18, 2019)

“Adding precisely aimed, escalated doses of radiation after patients no longer respond to immunotherapy reinvigorates the immune system in some patients with metastatic non-small-cell lung cancer (NSCLC), increasing progression-free survival (PFS). Findings of the phase II randomized trial were presented at the 61st Annual Meeting of the American Society for Radiation Oncology (ASTRO), Sept. 15-18 in Chicago.”

(#187) USPSTF updates BRCA cancer screening recommendations (Radiology Business August 20, 2019)

“The U.S. Preventative Services Task Force (USPSTF) released updated recommendations for BRCA1/2 testing, suggesting practitioners increase the use of genetic counseling and testing.

Specifically, the USPSTF recommends clinicians assess women with a personal or family history of breast, ovarian, tubal or peritoneal cancer associated with BRCA gene mutations using a brief risk assessment tool. Those with positive results should undergo genetic counseling, and if necessary, genetic testing—a USPSTF designated “B” recommendation.”

(#186) CEDM shows promise as breast cancer screening tool for high-risk women (Radiology Business August 27, 2019)

“Contrast-enhanced digital mammography (CEDM) could be an effective alternative to full-field digital mammography (FFDM) for screening women at an elevated risk of breast cancer, according to new findings published in Radiology.

The authors explored data from 904 patients who underwent baseline CEDM examinations for breast cancer screening from December 2012 to April 2016. In each instance, CEDM was either specifically ordered by the referring physician or performed for a clinical study. A majority (77.4%) of patients had dense breast tissue, 27.3% had a family history of breast cancer and 40.2% had a personal history with the disease.”

(#185) How Darkroom Photography Techniques Inspired a Radical Approach to Cancer Screening (MD+DI August 20, 2019)

“Tom Ramsay, an image processing expert and master photographer, has spent decades sharing his expertise with the world, from working on satellite imaging for the U.S. Navy, fingerprint image processing for the Department of Homeland Security, computer-based photo microscopy analysis of tuberculosis (TB) in Africa, and even restoring Thomas Edison’s movies for the Library of Congress. So when his cousin lost both of her daughters to breast cancer, Ramsay had a hard time understanding how such a thing was possible, given all the advanced imaging technology that exists.”

(#184) What Has Artificial Intelligence Done for Radiology Lately? (Radiology Business August 9, 2019)

“From basic sorting algorithms to sophisticated neural networks, AI and its offspring continue to generate buzz throughout medicine, business, academia and the media. Much of the chatter amounts to no more than hot air. The most farfetched imaginings are usually easy to spot and dismiss.

Yet accounts of real-world AI deployments—applications with strong potential to improve patient care while cutting costs—are amassing into a category of medical literature in its own right.”

(#183) How a large healthcare system reduced variation in radiology reports (Health Imaging August 15, 2019)

“A quality improvement project undertaken at a large academic medical center significantly reduced the variation in radiology report templates. The initiative may serve as an example of how radiology can move toward value-based care.

“In our practice, as at other large institutions, there was great variability in report structure among individual radiologists,” wrote Tony W. Trinh, MD, with the department of radiology at Brigham and Women’s Hospital in Boston, and colleagues. “Substantial differences in report structure, content, length, and degree of detail provided by different radiologists can be a source of confusion and frustration for referrers and patients.””

(#182) Breast Cancer Mortality and Aspirin Use Linked by DNA Methylation (Genetic Engineering and Biotechnology News August 12, 2019)

“Prior studies have suggested that women who take aspirin before being diagnosed with breast cancer (BC) may live longer than women who haven’t historically used aspirin, but study data is limited and inconsistent. Research headed by scientists at the University of North Carolina (UNC) at Chapel Hill has now found that DNA methylation may represent the missing link in this relationship. Their population-based study in more than 1,000 women with breast cancer found that global DNA methylation, and methylation of the promoters for two specific cancer-related genes, may impact on whether prediagnosis aspirin use can influence breast cancer-specific mortality, and death from all causes.”

(#181) Industry update: 3 reasons the mammography market may soon slow down (Radiology Business August 2, 2019)

“Growth in the mammography market may begin to slow down in the near future, according to a new analysis from Signify Research.

Author Imogen Fitt described mammography as the breast imaging industry’s “undisputed modality of choice,” but also noted that it could be in for a significant shift. And how did she come to that conclusion? In her analysis, Fitt provided three key reasons…”

(#180) Researchers survey radiology’s attitude toward synthesized digital mammography in DBT (Health Imaging August 13, 2019)

“Synthesized digital mammography (SM) was created to help reduce the radiation dose for patients undergoing digital mammography (DM) in digital breast tomosynthesis (DBT), so why haven’t more clinics adopted it?

Researchers of a new study published in the Journal of the American College of Radiology administered a survey to the 2,600 members of the Society of Breast Imaging to find out.

“Combination-dose DM and DBT screening over the lifetime of a screened woman will result in higher radiation dose than screening with DM alone,” wrote Samantha Zuckerman, MD, with the University of Pennsylvania, and colleagues. “Thus, it would be most beneficial to patients if the ‘dose DM’ portion of a DBT screen is replaced by an acceptable SM image so that the benefits of DBT could be maintained at a lower radiation dose than DM–DBT screening.””

(#179) Can mammography serve as a ‘dual test’ for breast cancer, CVD? (Health Imaging August 12, 2019)

“There’s a strong case to be made for mammography to become a “dual test” for both breast cancer screening and cardiovascular disease (CVD) prevention, according to a new review published in the European Journal of Radiology.

Breast cancer screening via mammography can easily detect breast arterial calcifications (BACs) which are associated with CVD and serve as an imaging biomarker for prevention of the disease, wrote Rubina Manuela Trimboli, with the department of biomedical sciences for health at the Università degli Studi di Milano in Milan, Italy, and colleagues.

“Thus, there is a strong rationale for mammography to serve as a preventive test beyond breast cancer screening, spotlighting on the heart and more comprehensively on CV risk,” Trimboli and colleagues wrote.”

(#178) AI helps pathologists diagnose difficult breast cancer cases (Health Imaging August 9, 2019)

“A new machine learning system created by UCLA researchers may help doctors classify breast cancers that are notoriously difficult to diagnose, according to an Aug. 9 study published in JAMA Network Open.

Preinvasive lesions, including some types of atypia and ductal carcinoma in situ (DCIS) can indicate higher cancer risk, wrote corresponding author Joann G. Elmore, MD, MPH, with UCLA’s Division of General Internal Medicine and Health Services Research, but diagnostic disagreements are “remarkably high” for such lesions. Machine learning has shown great promise for differentiating breast cancers, but studies have largely focused solely on tumor detection.”

(#177) AI Identifies New Breast Cancer Subtypes That May Help Personalize Diagnosis and Therapy (Genetic Engineering & Biotechnology News August 5, 2019)

“Scientists headed by a team at the Institute of Cancer Research, London (ICR) have used artificial intelligence (AI) and machine learning (ML) to discover five new subtypes of breast cancer that could help clinicians deliver the most effective therapies—including immunotherapy—for individual patients, as well as potentially direct the development of new anticancer drugs.

The computational tools find patterns in the genetic, molecular, and cellular make-up of primary luminal A-type breast tumors, which are analyzed alongside data on patient survival.”

(#176) Care journeys of breast-cancer patients illuminated by AI (AI in Healthcare August 2, 2019)

“Allowing natural language processing to pore over disparate data stored in electronic health records, researchers in Canada have shown the AI-based technology can reveal real-world experiences and outcomes of patients with stage III breast cancer.

Mark Levine, MD, of McMaster University and colleagues had their work published online Aug. 1 in JCO Clinical Cancer Informatics.”

(#175) AI improves accuracy, cuts reading times associated with DBT exams (Radiology Business July 31, 2019)

“Deep learning can improve the accuracy and efficiency of digital breast tomosynthesis (DBT) examinations, according to new findings published in Radiology: Artificial Intelligence.

The study’s authors developed and trained a deep learning system to identify suspicious findings on DBT images, hoping it could help reduce the longer reading times associated with screening patients with DBT. A group of 24 radiologists then read 260 DBT examinations with and without assistance from the deep learning system.”

(#174) Molecular markers of cancer classified with AI (AI in Healthcare July 29, 2019)

“AI and deep learning can extract molecular markets of breast cancer from tissue morphology and assist pathologists in a mass-scale molecular profiling, according to new research published in JAMA Network Open.

Researchers studied tissue microarray hematoxylin-eosin-stained images from more than 5,000 breast cancer patients. Using a deep learning model, researchers could profile cancer molecules with “practically no added cost and time,” lead author Gil Shamai, MSc, of the department of electrical engineering at Technion Israel Institute of Technology in Haifa, Israel, et al. wrote.”

(#173) Why do some patients decline DBT for breast cancer screening? (Health Imaging July 10, 2019)

“Breast cancer screening using digital breast tomosynthesis has risen rapidly in the United States, but that isn’t the case in all regions or across all institutions, according to a new study published in Current Problems in Diagnostic Radiology.

“Despite the advantages of reduced callback rates, higher sensitivity, and higher specificity associated with digital breast tomosynthesis (DBT) over traditional full-field digital mammography (FFDM), many patients declined DBT at our urban academic breast center,” wrote Kellie Chiu, with University of Maryland Medical Center’s Department of Diagnostic Radiology and Nuclear Medicine, and colleagues.”

(#172) Background parenchymal enhancement leads to abnormal breast MRI interpretations (Radiology Business July 26, 2019)

“High levels of background parenchymal enhancement (BPE) can have a negative impact on the diagnostic quality of breast MRI interpretations, according to new findings published in Academic Radiology.

“Because of the negative impact of breast density on the sensitivity and specificity of mammography, radiologists are required to document breast density in mammography reports and many states have enacted legislation requiring this information be shared directly with patients,” wrote Dorothy A. Sippo, MD, MPH, department of radiology at Massachusetts General Hospital in Boston, and colleagues. “If BPE has a similar impact on MRI performance, then comparable attention to its importance may be warranted.””

(#171) New AI tool may be a powerful force in cancer care (Health Imaging July 25, 2019)

“A deep learning platform created by researchers at the Dana-Farber Cancer Institute can identify cancer in radiology reports as well as clinicians, but in a fraction of the time, according to new research published July 25 in JAMA Oncology.

The model was trained on more than 14,000 imaging reports from 1,112 patients with lung cancer, manually read by human reviewers. After it was applied to another 15,000 reports, the algorithm predicted overall survival with similar accuracy to that of human assessments.”

(#170) MITA backs push to include DBT screening coverage for TRICARE beneficiaries (Health Imaging July 23, 2019)

“The Medical Imaging & Technology Alliance (MITA) released a statement July 23 cheering lawmakers’ efforts to make digital breast tomosynthesis (DBT) screening coverage standard for active and retired members of the military.

U.S. Representative Chrissy Houlahan (D-PA), along with numerous other members of Congress, addressed a letter to the Military Health System (MHS) urging its leadership to provide DBT coverage to TRICARE health beneficiaries. TRICARE is one of the few payers in the U.S. that does not include coverage for the screening exam.”

(#169) Informatics experts share 4 key use cases for AI in radiology (Radiology Business July 16, 2019)

“For radiology to truly benefit from AI’s potential, the specialty must learn how to get the most information possible out of all available digital data. The authors of a new analysis published by the Journal of the American College of Radiology explored this subject in detail, describing use cases critical for radiology to successfully evolve in the years ahead.

“In 2013 and 2014, the RSNA Radiology Informatics Committee and American College of Radiology (ACR) Commission on Informatics, along with senior leadership from both societies, held two joint retreats to identify gaps in technology that may impose future limitations in our digital workflow…””

(#168) Biodesix Looks to Become ‘the’ Lung Cancer Detection Co. With New Acquisition (MDDI Online June 28, 2019)

““Our focus is becoming ‘the’ lung cancer diagnostic solution company,” Scott Hutton, COO of Biodesix, told MD+DI. “With that we know we need multiple diagnostics tests for different times within a patient’s care continuum. With GeneStrat and VeriStrat being our legacy products – we were looking more late stage.”

The firm acquired U.K.-based Oncimmune’s laboratory and incidental pulmonary nodule malignancy test in the U.S. Oncimmune’s U.S. operations, including a CLIA lab in De Soto, KS, will transition to Biodesix on Nov. 1. The lab is the sole U.S. provider of Oncimmune’s EarlyCDT -Lung test.”

(#167) The Cost of Surviving Cancer (Health Lifestyle Arena June 20, 2019)

“Over the past few years, I’ve written a number of posts talking about different cancers and new cancer treatments. Fifty years ago, nearly any diagnosis of cancer would have been a death sentence, but today, surviving many cancers has drastically increased.

According to the American Cancer Society:

Lung cancer death rates declined 48% from 1990 to 2016 among men and 23% from 2002 to 2016 among women. From 2011 to 2015, the rates of new lung cancer cases dropped by 3% per year in men and 1.5% per year in women. The differences reflect historical patterns in tobacco use, where women began smoking in large numbers many years later than men and were slower to quit. However, smoking patterns do not appear to explain the higher lung cancer rates being reported in women compared with men born around the 1960s.”


(#166) Risk-based breast cancer screening program finds significant success (Radiology Business June 20, 2019)

“As researchers and advocates in the United States debate the merits of risk-based breast cancer screening vs. age-based screening, a risk-based program in Northern Ireland (NI) has found significant success. A new study published in Clinical Radiology examined the program in detail.

The program began in April 2013 at the urging of the chief medical officer for NI. A multidisciplinary working group was established to work out the details and get providers throughout the area on the same page, and the researchers examined four years of data for their study.”

(#165) A key benefit, and potential harm, of adding MRI to breast cancer screening programs (Radiology Business June 4, 2019)

“Surveillance MRI can help imaging providers detect more breast cancers, according to a new study published in Radiology. However, it also leads to a much higher biopsy rate.

“People often think more testing is better,” lead author Karen J. Wernli, PhD, an associate investigator at the Kaiser Permanente Washington Health Research Institute in Seattle, said in a prepared statement. “That might be true for some women, but not necessarily all. It’s important for clinicians and women to be aware of both the benefits and harms that can come from imaging.””

(#164) Novel language modeling approach correlates radiology, pathology reports (Health Imaging June 4, 2019)

“Correlating radiology and pathology reports is an ongoing challenge on the path toward achieving multidisciplinary patient care. One researcher has gotten a little closer to that goal with the help of deep learning techniques, sharing findings in the Journal of the American College of Radiology.

The method uses a language-modeling approaches trained on data from multiple hospitals and ambulatory sites and can serve as an important basis to continually improve specificity and user preferences in automatically correlating radiology and pathology reports, according to the study’s only author, Ross Filice, MD, with MedStar Georgetown University Hospital, Washington, D.C.”

(#163) Breast MRI found to result in more biopsies than mammography (Health Data Management June 4, 2019)

“The use of magnetic resonance imaging brings many benefits to cancer care, but the imaging modality appears to prompt more biopsies than are necessary.

A recent study found that breast cancer patients who were screened with MRIs underwent twice as many biopsies as those that were screened with mammography alone.”

(#162) Same-day biopsy program can address disparities among breast cancer patients (Radiology Business June 3, 2019)

“Implementing a same-day biopsy program can help providers address ongoing disparities in patient care, according to a new study published in the Journal of the American College of Radiology.

A team from Massachusetts General Hospital in Boston conducted the study, noting that numerous disparities are present in breast cancer care in the United States.”

(#161) AI can dramatically reduce mammography reads for radiologists (Health Imaging May 31, 2019)

“Machine learning can reduce a radiologists workload by lowering the number of screening mammograms they’re required to read while preserving accuracy, according to results of a feasibility study published in the Journal of the American College of Radiology.

Trent Kyono, with the Department of Computer Science, University of California Los Angeles, and colleagues created their autonomous radiologist assistant (AURA)—a modified version of a previous clinical decision support system—to determine if it could diagnose mammograms as negative while maintaining diagnostic accuracy and noting which scans would still need to be read by a radiologist.”

(#160) ASCO: In early study results, Grail’s blood test identifies 12 cancers before they spread (Fierce Biotech May 31, 2019)

“New, early data from Grail showed its liquid biopsy test was not only able to detect the presence of 12 different kinds of early-stage cancer but could also identify the disease’s location within the body before it spreads using signatures found in the bloodstream.

The test also demonstrated a very low rate of false positives, at 1% or less. The former Fierce 15 winner presented the returns from a sub-study of its Circulating Cell-free Genome Atlas (CCGA) project at this year’s annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago.”

(#159) Deep-learning tool smartly steers patients toward—or away from—breast biopsy (AI in Healthcare May 30, 2019)

“Researchers in Texas and Taiwan have collaborated to develop a deep-learning tool that can precisely asses the risk of breast cancer—and with it the need for biopsy—in patients with lesions of questionable concern found in mammograms.

Their key achievement is training an algorithm to home in on a well-defined subgroup of patients, those with mammography findings categorized as BI-RADS 4 (on a scale of 0 to 6 developed by the American College of Radiology).”

(#158) How many mammography reads does it take to reach peak performance? (Health Imaging May 28, 2019)

“New research suggests annual reading volumes between 4,000 and 10,000 mammograms may produce the highest performance among screening programs with independent double reading.

In addition, cumulative reading volumes of more than 20,000 mammograms resulted in peak radiologic performance, according to results of a new study published May 28 in Radiology.”

(#157) Google’s cancer-spotting AI outperforms radiologists in reading lung CT scans (Fierce BioTech May 22, 2019)

“Google’s artificial intelligence development has reached a milestone in lung cancer imaging and prediction, with a CT scan model being able to diagnose cases as well as or better than a group of six radiologists.

Alongside researchers at Northwestern University, New York University-Langone Medical Center and Stanford Medicine, Google’s AI team was able to generate an overall prediction of malignancy from 3D volumetric scans, as well as identify subtle lung nodules.”

(#156) How radiologists can use mammography to improve lung cancer screening utilization (Radiology Business May 17, 2019)

“Many women who undergo screening mammography are also eligible for lung cancer screening (LCS), according to a new study published by the Journal of the American College of Radiology. Yet LCS utilization in the United States remains considerably low.

“LCS with low-dose CT has been shown to reduce deaths from lung cancer by 15% to 20% in high-risk current or former smokers,” wrote Diego López, MPH, Harvard Medical School in Boston, and colleagues. “The United States Preventive Services Task Force recommends annual screening for this patient population…””

(#155) JAMA: 3 concerns surrounding mandatory breast density notification (Health Imaging May 15, 2019)

“On February 15 of this year, Congress passed national breast density legislation, which mandates all mammography reports and summaries notify women of their breast density.

In a recent JAMA commentary, a trio of researchers questioned whether the law will actually help patients, sharing some of their most pressing concerns.”

(#154) Short-interval follow-up MRI helps ID early stage breast cancer (Health Imaging May 8, 2019)

“Short-interval follow-up MRI can identify early stage breast cancer and reduce unnecessary biopsies, reported authors of a study to be presented at the American Roentgen Ray Society Annual Meeting in Honolulu.

Co-researcher Christine Edmonds, MD, of the department of radiology at Massachusetts General Hospital (MGH) and colleagues analyzed the frequency and cancer yield of American College of Radiology (ACR) Breast Imaging Reporting and Data System (BI-RADS) 3 lesions in patients who received baseline and non-baseline screening MRIs. The team defined non-baseline as those preceded by at least one screening exam.”

(#153) Which diffusion-MRI strategy best IDs malignant breast lesions? (Health Imaging April 24, 2019)

“Diffusion-weighted imaging techniques for quantitatively identifying benign and malignant breast lesions achieved comparable diagnostic accuracies, according to a meta-analysis of three methods published April 23 in Radiology.

“Whereas previous meta-analyses have assessed the performance of the (apparent diffusion coefficient) ADC model in differentiating between benign and malignant lesions, more advanced diffusion techniques aim to improve on the results of quantitative (diffusion-weighted imaging) DWI,” wrote Gabrielle C. Baxter from the department of radiology at the University of Cambridge School of Clinical Medicine in Cambridge, England, and colleagues.”

(#152) The ACR’s 4 legislative priorities for Capitol Hill Advocacy Day (Health Imaging May 6, 2019)

“On May 22, more than 400 American College of Radiology (ACR) members will speak with their elected federal representatives to discuss four legislative priorities as part of Capitol Hill Advocacy Day at the 2019 ACR Annual Meeting.

Limiting surprise medical bills

“Issues surrounding beneficiaries being burdened with high out-of-pocket costs and inadequate provider networks present real issues for patients in need of life saving diagnostic imaging services,” according to an ACR position statement. “The problem of unanticipated out-of-network bills is complex, and requires a balanced approach to resolve.”

A key problem, according to the ACR, is that health insurance plans are leaning on a narrow network of providers to control costs, and as a result even patients who make sure they receive in-network care are still burdened by…”

(#151) MGH, MIT researchers create AI tool that predicts risk of breast cancer (Health Data Management May 9, 2019)

“A deep learning model is able to accurately assess breast tissue density—an independent risk factor for breast cancer—in mammograms.

In a new study of the model, developed by Massachusetts General Hospital and MIT, nearly 90,000 full-resolution screening mammograms from about 40,000 women were used to train, validate and test the deep learning model.

“We developed a deep learning model that uses full-field mammograms and traditional risk factors, and found that our model was more accurate than the Tyrer-Cusick model (version 8), a current clinical standard,” conclude researchers in a study published earlier this week in the journal Radiology.”

(#150) All women 25 years old and older should undergo a breast cancer risk assessment (Radiology Business May 3, 2019)

“All women 25 years old and older should undergo a breast cancer risk assessment, according to a new position statement published by the American Society of Breast Surgeons (ASBrS). Annual mammograms, beginning at the age of 40, are recommended if women have an average risk of developing breast cancer. If the risk is greater, annual mammograms and supplemental imaging are recommended.

In addition, the ASBrS emphasized the effectiveness of digital breast tomosynthesis (DBT), also known as 3D mammography.

“Where available, 3D mammography is the preferred sole modality for women with an average risk for breast cancer,” according to the statement. “It is also important to note that most current 3D mammography units result in no greater radiation exposure than traditional 2D units.””

(#149) AI predicts breast cancer risk 5 years in advance (Health Imaging May 7, 2019)

“A team of researchers from MIT and Massachusetts General Hospital (MGH) have created an AI model capable of predicting a patient’s breast cancer risk five years in advance.

The deep learning (DL) model was also equally as accurate for racial minorities who have proven to be more likely to die from cancer, such as black women, according to a May 7 study published in Radiology.”

(#148) Georgia’s breast density legislation signed into law (Radiology Business May 7, 2019)

“Georgia Gov. Brian Kemp has signed the state’s breast density legislation into law. The bill goes into effect on July 1.

HB 62 requires mammography providers to notify patients about their breast density. It is also known as “Margie’s Law,” named after patient advocate Margie Singleton, who had breast cancer missed by a mammogram due to her dense breast tissue.

According to the legislation, the text sent to patients should read as follows…”

(#147) How the screening method impacts survival outcomes for patients with DCIS (Radiology Business April 30, 2019)

“Patients with screening-detected ductal carcinoma in situ (DCIS) who were screened with mammography and ultrasound (US) have similar disease-free survival (DFS) rates, according to a new study published in Radiology. In patients with screening mammography-detected DCIS, an association was observed between dense breasts and second breast cancer.

“Several studies have reported that screening-detected DCIS shows better DFS than does symptomatic DCIS,” wrote lead author Seung Hee Choi of the Sungkyunkwan University School of Medicine in Seoul, Korea, and colleagues. “To our knowledge, however, no studies have evaluated the association between the screening method (mammography or US) and survival outcome after treatment of DCIS.””

(#146) Radiotherapy shown beneficial in early stage breast cancer patients (Health Imaging April 30, 2019)

“Radiotherapy combined with hormonal therapy after surgery significantly reduced the chance of recurrence in women with early hormone receptor-positive (HR+) breast cancer, according to results of a 10-year trial presented at the European Society for Radiotherapy and Oncology (ESTRO) 38 conference in Milan, Italy.

Results of the 8 A arm of the Australian Breast and Colorectal Cancer Study Group found cancer did not return in the same breast in 97.5% of women who underwent whole-breast irradiation (WBI) and hormonal therapy after a 10 year follow-up period. In women who only received hormonal therapy, that fraction was 92.4%.”

(#145) Global handheld ultrasound market could surpass $400M by 2023 (Radiology Business April 29, 2019)

“The handheld ultrasound market has been slow to take off in recent years, but a burst of growth could be on the horizon, according to a new report from Signify Research.

Simon Harris, the report’s author, noted that cardiologists and emergency medicine specialists made up much of the handheld ultrasound market’s initial wave of growth. This was followed by what Harris called “the current wave” of growth, which includes office-based specialists who want the technology so they provide a wider range of services during initial appointments with patients.”

(#144) ACP shares new breast cancer screening guidelines, imaging societies push back (Radiology Business April 8, 2019)

“The American College of Physicians (ACP) now recommends that average-risk women with no symptoms undergo breast cancer screening with mammography every other year, beginning at the age of 50. The ACP explained its decision through a new guidance statement published in Annals of Internal Medicine.

“Beginning at age 40, average-risk women without symptoms should discuss with their physician the benefits, harms, and their personal preferences of breast cancer screening with mammography before the age of 50,” ACP President Ana María López, MD, said in a prepared statement. “The evidence shows that the best balance of benefits and harms for these women, which represents the great majority of women, is to undergo breast cancer screening with mammography every other year between the ages of 50 and 74.””

(#143) Genetic testing for newly diagnosed breast cancer patients could save $50M (Radiology Business April 25, 2019)

“In 2018, results from the TAILORx clinical trial revealed that genetic testing could help a majority of women with HR-positive, HER2-negative, axillary node-negative breast cancer bypass chemotherapy since it would not benefit them any more than hormone therapy alone. Now, researchers have determined that the widespread use of such testing could lead to approximately $50 million in savings for the first year of breast cancer care in the United States.

The team, including lead author Angela Mariotto, PhD, of the National Cancer Institute, shared its findings in JNCI: Journal of the National Cancer Institute.”

(#142) Which diffusion-MRI strategy best IDs malignant breast lesions? (Health Imaging April 24, 2019)

“Diffusion-weighted imaging techniques for quantitatively identifying benign and malignant breast lesions achieved comparable diagnostic accuracies, according to a meta-analysis of three methods published April 23 in Radiology.

“Whereas previous meta-analyses have assessed the performance of the (apparent diffusion coefficient) ADC model in differentiating between benign and malignant lesions, more advanced diffusion techniques aim to improve on the results of quantitative (diffusion-weighted imaging) DWI,” wrote Gabrielle C. Baxter from the department of radiology at the University of Cambridge School of Clinical Medicine in Cambridge, England, and colleagues.”

(#141) 4 steps to implementing abbreviated breast MRI screening into practice (Radiology Business April 22, 2019)

“The high sensitivity associated with breast MRI makes it an effective tool for detecting breast cancer, but the costs and long acquisition times have kept it from being embraced as a supplemental screening option. Researchers at one institution adopted an abbreviated protocol (AP) for breast MRI for patients with dense breasts, discussing their process in the American Journal of Roentgenology.

It took a full year to implement the protocol as a screening option, the authors noted, as it involves making key decisions and getting various stakeholders on board. These are four key steps providers must take to make such a protocol a reality:”

(#140) Free online tool reads chest X-rays as well as physicians (AI in Healthcare April 1, 2019)

“A free web tool known as “Chester the AI Radiology Assistant” can assess a person’s chest X-rays online within seconds, ensuring patients’ private medical data remains secure while predicting their likelihood of having 14 diseases.

Chester, though still rudimentary, can process a user’s upload and output diagnostic predictions for atelectasis, cardiomegaly, effusion, infiltration, masses, nodules, pneumonia, pneumothorax, consolidation, edema, emphysema, fibrosis, pleural thickening and hernias with 80 percent accuracy. A green-and-red sliding scale pinpoints the diagnostic probability for each condition, ranging from “healthy” to “risk.””

(#139) FDA working on new steps for regulating AI devices (Health Imaging April 3, 2019)

“The FDA announced Tuesday, April 3, that it is working on a new framework to regulate AI-based medical devices that continually learn from healthcare data.

Scott Gottlieb, MD, who announced his resignation as commissioner of the FDA last month, released a discussion paper outlining the administration’s approach to keep up with the rapid advancement of AI algorithms and ensure their safety. The agency is also asking for feedback about the paper due by June 3.”

(#138) Should women with dense breasts pursue additional screening? Here’s what radiologists think (Radiology Business April 3, 2019)

“When women learn that they have dense breast tissue after a mammogram, should they seek out supplemental screening? A new study published in the Journal of Breast Imaging asked radiologists what they currently recommend for patients at all risk levels.

“Currently, there are no guidelines recommending the use of supplemental screening in women with dense breasts, although there is legislation in over 30 states requiring women be notified of breast density,” wrote Tisha Singer, MD, Rhode Island Hospital and Alpert Medical School of Brown University in Providence, Rhode Island, and colleagues.”

(#137) AI model predicts a patient’s breast cancer risk from single MR image (Radiology Business April 2, 2019)

“Researchers have developed a deep learning (DL) model that assesses a woman’s five-year cancer risk with a single breast MR image, sharing their findings in the American Journal of Roentgenology.

“Although a large number of risk assessment models exist for the general screening population, they are not readily applicable to high-risk patients,” wrote Tally Portnoi, department of electrical engineering and computer science at Massachusetts Institute of Technology in Cambridge, and colleagues.”

(#136) Older women benefit from breast cancer screening with DBT (Radiology Business April 2, 2019)

“Breast cancer screening with digital breast tomosynthesis (DBT) provides significant value to older women, according to a new study published in Radiology.

The researchers analyzed data from more than 15,000 women aged 65 years or older who underwent digital mammography (DM) alone from March 2008 to February 2011, before their institution had integrated DBT into clinical practice. The team then explored data from more than 20,000 women aged 65 years or older who underwent DBT from January 2013 to December 2015.”

(#135) Breast Cancer Gene Expression Altered by Walnut Consumption (Genetic Engineering & Biotechnology News March 29, 2019)

“In a small clinical study, investigators from Marshall University School of Medicine found that the consumption of two ounces of walnuts per day for about two weeks significantly changed gene expression in confirmed breast cancers. The findings from the study were published recently in Nutrition Research through an article titled “Dietary walnut altered gene expressions related to tumor growth, survival, and metastasis in breast cancer patients: A pilot clinical trial.””

(#134) Breast density assessments vary depending on the screening technique (Radiology Business March 20, 2019)

“Breast density assessments using digital breast tomosynthesis (DBT) and synthetic mammography (SM) vary significantly compared to those performed using standard digital mammography (DM), according to a new study published by Radiology.

The authors examined data from more than 24,000 women who underwent mammographic breast cancer screening at the Hospital of the University of Pennsylvania (HUP) in Philadelphia between 2010 and 2017. Of the more than 60,000 examinations, 14.7 percent were performed using DM only, and 50.7 percent were performed using DM and DBT together. The final 34.6 percent were performed with SM and DBT together.”

(#133) FDA proposed rule ‘modernizes’ mammography screening, includes breast density reporting (Radiology Business March 27, 2019)

“The FDA announced Wednesday, March 27, that it is taking action to “modernize” breast cancer screening in the United States by amending the Mammography Quality Standards Act of 1992 with a new proposed rule.

“Breast cancer is one of the most worrisome health concerns facing women,” Scott Gottlieb, MD, outgoing FDA commissioner, said in a prepared statement. “The FDA plays a unique and meaningful role in the delivery of quality mammography to help patients get accurate screening to identify breast health problems early, when they can be effectively addressed…””

(#132) PET biomarkers may lead to individualized treatment for breast cancer (Applied Radiology March 22, 2019)

“Positron emission tomography/computed tomography (PET/CT) scan biomarkers show potential for identifying breast cancer patients who may be able to forgo conventional chemotherapy before surgery. Researchers at the Johns Hopkins Kimmel Cancer Center have identified a biomarker that may accurately predict which patients with dual human epidermal growth factor receptor 2 (HER2)-positive breast cancer might benefit from standalone HER2-targeted agents, without requiring standard chemotherapy. They reported their findings online Feb. 5, 2019, in the Journal of Clinical Oncology.”

(#131) Using water and gold, Australian researchers discover ‘universal cancer biomarker’ (Fierce Biotech December 5, 2018)

“Australian researchers at the University of Queensland have discovered a unique DNA structure that appears to be shared by many cancers and could be used to develop a simple diagnostic test that could be performed in under 10 minutes with the naked eye.

When circulating tumor DNA fragments are placed in water, they begin to fold into 3D shapes different than DNA from healthy cells—driven by the dense clusters of methyl groups found along DNA molecules that have been reprogrammed by cancer.”

(#130) Does supplemental whole-breast ultrasound provide significant value? (Radiology Business March 21, 2019)

“Supplementing screening mammography with whole-breast ultrasound may not be worth the trouble, according to new findings published in JAMA Internal Medicine.

The study’s authors noted that many researchers have advocated for whole-breast ultrasound and mammography to be used together when screening women with dense breast tissue. Others, however, have found the evidence is unclear.”

(#129) An alternative approach for locating a mammographic lesion by ultrasound using a simple x,y coordinate system ( Nov/Dec, 2012)


We present an accurate and reliable method for localizing a mammographic lesion by ultrasound using a simple coordinate system. It does not require special grid equipment or additional personnel. We use our system, step-by-step, on a sample patient and include appropriate image documentation. The nipple is the point of reference or “origin”. The lesion is located on ultrasound using its x and y coordinates, which are the two distances from the nipple in the horizontal and vertical axes, measured with an ordinary ruler or caliper tool. The true distance from the nipple can also easily be measured and reported. Our method is reproducible and shortens ultrasound exam times to less than 10 minutes.”

(#128) Use of Contrast-Enhanced MRI in Management of Discordant Core Biopsy Results ( March 5, 2019)


Evaluating concordance between core biopsy results and imaging findings is an integral component of breast intervention. Pathologic results deemed benign discordant reflect concern that a malignancy may have been incorrectly sampled. Standard of care currently is surgical excision, although a large percentage of these lesions will be benign at final pathologic analysis. The purpose of this study was to determine whether inclusion of contrast-enhanced MRI would optimize patient care.”

(#127) Accurately Identifying Cancer-Causing Mutations from Archival Tumor Samples (Genetic Engineering Biotechnology News March 21, 2019)

“Scientists at the Translational Genomics Research Institute (TGen), an affiliate of City of Hope, report the development of LumosVar, a computer program that can help identify cancer-causing mutations from patient tumor samples. The study (“Leveraging Spatial Variation in Tumor Purity for Improved Somatic Variant Calling of Archival Tumor Only Samples”) appears in Frontiers in Oncology.

“Archival tumor samples represent a rich resource of annotated specimens for translational genomics research. However, standard variant calling approaches require a matched normal sample from the same individual, which is often not available in the retrospective setting, making it difficult to distinguish between true somatic variants and individual-specific germline variants.”

(#126) Skin Cancer Risk Reduced by Topical Immunotherapy (Genetic Engineering Biotechnology News March 21, 2019)

“Sunscreen may not be the only ointment that helps prevent skin cancer. A cream that combines 5-fluorouracil (5-FU) and a synthetic form of vitamin D has been shown to reduce the risk that precancerous skin lesions will progress to squamous cell carcinoma (SCC), the second most common form of skin cancer.

A couple of years ago, the combination cream was evaluated as a means of eliminating actinic keratoses, precancerous lesions that emerge in sun-damaged skin. Although the chance of an individual lesion progressing to cancer is only 1%, most SCCs develop from existing actinic keratosis lesions.”

(#125) Increased background parenchymal enhancement level a key biomarker for breast cancer risk (Radiology Business March 20, 2019)

“Increased background parenchymal enhancement (BPE) levels at breast MRI are associated with a greater risk of developing breast cancer within a year, according to new findings published in the American Journal of Roentgenology.

“Identifying patients with hormonally responsive breast tissue has important clinical implications,” wrote Dorothy A. Sippo, MD, department of radiology at Massachusetts General Hospital in Boston, and colleagues.”

(#124) Breast density assessments vary depending on the screening technique (Radiology Business March 20, 2019)

“Breast density assessments using digital breast tomosynthesis (DBT) and synthetic mammography (SM) vary significantly compared to those performed using standard digital mammography (DM), according to a new study published by Radiology.

The authors examined data from more than 24,000 women who underwent mammographic breast cancer screening at the Hospital of the University of Pennsylvania (HUP) in Philadelphia between 2010 and 2017. Of the more than 60,000 examinations, 14.7 percent were performed using DM only, and 50.7 percent were performed using DM and DBT together. The final 34.6 percent were performed with SM and DBT together.”

(#123) What do providers think about Canada’s updated breast cancer screening guidelines? (Radiology Business March 19, 2019)

“In December 2018, the Canadian Task Force on Preventive Health Care issued updated breast cancer screening guidelines that recommended women aged 50 to 74 seek screening every two or three years and women aged 40 to 49 not undergo screening. Opinions vary on the effectiveness of these guidelines, as one can see by reading two recent columns published by the Toronto Star.

Physician Lisa Del Giudice, MD, MSc, of Cancer Care Ontario wrote that the task force did the right thing. Jean Seely, MDCM, a breast radiologist at The Ottawa Hospital, wrote that updating the guidelines was a mistake.”

(#122) In another I-O first for Roche, Tecentriq nabs blockbuster small cell lung cancer nod (Fierce Pharma March 19, 2019)

“Just a week after Roche’s Tecentriq became the first immuno-oncology agent the FDA approved for triple-negative breast cancer, the anti-PD-L1 drug has clinched another first-in-class approval—this time in lung cancer.

The Swiss drugmaker said on Tuesday that the FDA had greenlighted Tecentriq in combination with chemotherapy for treatment of previously untreated extensive-stage small cell lung cancer (ES-SCLC), making it the first cancer immunotherapy in the setting and the first FDA-approved option for the disease in more than 20 years.”

(#121) PET Scans Show Biomarkers Could Spare Some Breast Cancer Patients from Chemotherapy (Imaging Technology News March 18, 2019)

“A new study of positron emission tomography (PET) scans has identified a biomarker that may accurately predict which patients with one type of HER2-positive breast cancer might best benefit from standalone HER2-targeted agents, without the need for standard chemotherapy. The study was conducted by researchers at the Johns Hopkins Kimmel Cancer Center in an effort to further individualize therapy and avoid over-treating patients.”

(#120) How has Your Environment Altered Your DNA? Your Urine Has the Answers (Technology Networks November 28, 2018)

“Over the course of a lifespan, from conception to death, each person encounters a wide variety of environmental stressors such as pollution, tobacco smoke, the sun’s rays, pharmaceutical agents and some constituents of food. Evidence of the exposure and a person’s ability to metabolize these stressors is all hiding in the urine.”

(#119) FHIR future now burning brighter for HL7 – Video (Health Data Management March 19, 2019)

“Chuck Jaffe, MD, CEO of Health Level 7, couldn’t have anticipated the rush to adoption of the FHIR standard, solidified by the rules recently proposed by federal agencies to use it as a basis for achieving interoperability in healthcare. Now, Jaffe sees more benefits ahead as FHIR can play a key role in other areas of healthcare.”

(#118) Smart pills filled with tiny needles could inject medicine directly into your stomach (Technology Review February 8th, 2019)

“Good news if you hate needles. Vaccinations, insulin injections, or intravenous drips could one day be replaced by smart pills that inject the medicine directly into your stomach.

What’s new: Many pharmaceutical compounds simply aren’t suited to being taken orally, because they can’t survive the stomach’s harsh, acidic environment. A new device could overcome that problem, allowing virtually any medication to be swallowed, according to a paper published in Science this week.”

(#117) Breast imaging referrers ordering more MRI scans following legislation (Radiology Business February 22, 2019)

“Referring physicians who have the option to send women for breast MRI are unclear on the exam’s clinical usefulness. That goes for specialists as well as primary-care providers. However, at an academic hospital system in Boston, all referring providers have been ordering more breast MRI since Massachusetts began requiring mammographers to inform patients in writing of their breast density.

So found breast radiologists at Beth Israel Deaconess Medical Center when they surveyed their referral base. The Harvard researchers had their findings published online in The Breast.”

(#116) Understanding Breast Cancer ( March 15, 2019)

“We hear a lot about breast cancer but how much do we really know that explains what we hear? Do you know the different types of breast cancer or what the different stages really mean?

According to the American Cancer Society, breast cancer is broken down into 2 main categories – in situ and invasive. In situ means it is still contained in the infected tissue and invasive means that it has spread to other areas.”

(#115) 4 Future Technologies That Will Shape Radiology (Diagnostic Imaging  March 12, 2019)

“Be it films, digital images, or integrated file-sharing systems, radiology has historically been the leader in applying technological advancements to workflow and patient care. That trend shows no slackening.

According to industry leaders, 2019 will again be a year where you’ll be introduced to new technologies and see wider-spread implementation of new tools to enhance the way you work and provide services to your patients.

Here are several technologies to consider investing in this year and beyond.”

(#114) FDA Allows Treatment of Depression with Club Drug’s Cousin ( March 6, 2019)

“A mind-altering medication related to the club drug Special K won U.S. approval Tuesday for patients with hard-to-treat depression, the first in a series of long-overlooked substances being reconsidered for severe forms of mental illness.

The nasal spray from Johnson & Johnson is a chemical cousin of ketamine, which has been used for decades as a powerful anesthetic to prepare patients for surgery. In the 1990s, the medication was adopted as a party drug by the underground rave culture due to its ability to produce psychedelic, out-of-body experiences. More recently, some doctors have given ketamine to people with depression without formal FDA approval.”

(#113) How to Reduce Wasteful Imaging (Diagnostic Imaging December 6, 2019)

“For more than a decade, the specter of unnecessary imaging and over-utilization has plagued radiology. Not only has it been costly, but it’s also exposed countless patients to unneeded—and cumulatively harmful—radiation.

But, with radiologists being the gatekeepers to advanced imaging services, it begs the question: how much responsibility do you, as providers, have in controlling how much imaging is ordered and completed within the healthcare environment? And, what, if anything, can you do to ensure your referring physicians and your facility overall aren’t contributing to the problem?

According to several industry leaders, it’s a role you’re obligated to take on.”

(#112) CT, Mammograms Offer Clues to Preventing Heart Problems After Cancer Treatment (Imaging Technology News March 13, 2019)

“An imaging procedure commonly performed before starting cancer treatment can provide valuable clues about a patient’s risk for heart problems in the months and years after treatment. However, this information is not always reported and is rarely acted upon in current practice, according to research being presented at the American College of Cardiology’s 68th Annual Scientific Session, March 16-18 in New Orleans.”

(#111) Breast cancer prediction models more effective when they include family history data (Radiology Business February 26, 2019)

“Breast cancer prediction models based on family history are more effective than those that do not focus on that information, according to a new study published in The Lancet Oncology.

The authors studied data on more than 15,000 women from Australia, Canada and the United States who belonged to the Breast Cancer Prospective Family Study Cohort. All women analyzed for the study were between the ages of 20 and 70, did not have breast cancer when they were recruited into the cohort and had an available family history of breast cancer.”

(#110) Second-opinion reviews of breast MRI studies provide value (Radiology Business March 12, 2019)

“Second-opinion breast MRI reviews by subspecialized radiologists can improve patient management and increase cancer detection, according to findings published in the Journal of the American College of Radiology.

“Breast imaging is subject to interobserver variability, and studies show breast imaging specialists detect more cancers than general radiologists,” wrote author R. Jared Weinfurtner, MD, Moffit Cancer Center in Tampa, Florida, and colleagues.”

(#109) Study links type 2 diabetes to aggressive breast cancer (Cardiovascular Business February 28, 2019)

“Women with type 2 diabetes are more likely than those without to develop more advanced, aggressive forms of breast cancer, Reuters reported of a study Feb. 27.

The study, which involved 6,267 women diagnosed with breast cancer between 2002 and 2014, examined the likelihood of developing advanced cancers when diabetes was present versus when it wasn’t. A quarter of the women recruited for the study had been previously diagnosed with diabetes.”

(#108) Inappropriate use of BI-RADS Category 3: Learning from mistakes (Applied Radiology January-February, 2019)

“Breast imaging subspecialists and general radiologists who interpret breast images should adhere to the unique lexicon of the American College of Radiology Breast Imaging Reporting and Data System Atlas (ACR BI-RADS®). The atlas was designed to ensure that breast findings are appropriately analyzed and correctly designated to one of seven BI-RADS categories, each of which implies a specific management recommendation. BI-RADS 3 was created to help reduce the number of false-positive biopsies, while maintaining a high rate of early cancer detection.”

(#107) IBM uses machine learning to detect early Alzheimer’s in blood samples (FierceBiotech March 11, 2019)

“Long before memory loss occurs in patients with Alzheimer’s, the protein amyloid-beta—which has been implicated in the formation of brain tangles that characterize the disease—starts building up in the spinal fluid. Problem is, detecting the protein there requires an invasive procedure that’s done under anesthesia, making it impossible to deploy on a widespread basis for the early detection of Alzheimer’s.

Researchers at IBM in Australia have developed an alternative to spinal fluid testing: a blood test that they say could predict the buildup of amyloid-beta in spinal fluid with up to 77% accuracy.”

(#106) Alzheimer’s Disease Signs Detected by Noninvasive Eye Scan (Genetic Engineering & Biotechnology News March 11, 2019)

“Researchers at Duke Eye Center have demonstrated how a noninvasive imaging technique can rapidly detect changes to the retina that can indicate Alzheimer’s disease (AD). The technique, known as optical coherence tomography angiography (OCTA), detects changes to or deterioration of the tiny blood vessels at the back of the eye, and is being used by researchers to study the connection between the retina and Alzheimer’s disease.”

(#105) FDA approves immunotherapy regimen for breast cancer (Radiology Business March 8, 2019)

“The FDA has granted accelerated approval to the combination of atezolizumab, an antibody marketed by Genentech under the name Tecentriq, and chemotherapy for certain patients with metastatic triple-negative breast cancer. For patients to be eligible, it must be determined by an FDA-approved test that the cancer is PD-L1 positive.

“The Tecentriq regimen is an exciting new treatment option for certain people living with metastatic triple-negative breast cancer, a difficult-to-treat form of the disease,” Hayley Dinerman, executive director of the Triple Negative Breast Cancer Foundation, said in a prepared statement.”

(#104) Coronary Artery Calcium Scanning Is Not a Magic 8 Ball (Cardiovascular Business March 8, 2019)

“Doc, am I going to have a heart attack? This is one of the most common questions that patients ask in my office. The truth is, I have no way of predicting the future. They could have a heart attack at any time for all I know. I empathize with their worries, but once I have optimized their risk factors I am often stuck telling them something along the lines of, Well, I don’t have a Magic 8 Ball, but as far as I can tell, you’re doing just fine. Although no test can predict the future, the coronary artery calcium scan (CACS) is near the front of the pack in this regard. Why? Because a coronary artery calcium score outperforms all other risk factors used today in predicting future cardiovascular events.”

(#103) What CT scans, mammograms can reveal about a patient’s heart health (Radiology Business March 8, 2019)

“CT scans can reveal valuable information about a patient’s heart health, even if the scan was not specifically ordered for that purpose. According to findings to be presented at the American College of Cardiology’s 68th Annual Scientific Session (ACC.19), however, radiologists do not always include heart-related findings in their reports.

“This is essentially free information because the patients are undergoing the CT scans anyway, and we’d like to see it reported more frequently,” Matthew Hooks, MD, a resident physician at the University of Minnesota in Minneapolis and the study’s lead author, said in a prepared statement.”

(#102) Deep neural network matches pathologists’ ability to identify lung cancer (AI in Healthcare March 8, 2019)

“A deep neural network crafted by research specialists at Dartmouth’s Norris Cotton Cancer Center identified different types of lung adenocarcinoma as well as practicing pathologists in a recent study, according to work published March 4 in Scientific Reports.

“Classification of histologic patterns in lung adenocarcinoma is critical for determining tumor grade and treatment for patients,” first author Jason W. Wei and colleagues wrote in the journal. “However, this task is often challenging due to the heterogeneous nature of lung adenocarcinoma and the subjective criteria for evaluation.””

(#101) How soon do women want to know their mammogram results? (Radiology Business February 20, 2019)

“Most women are willing to wait for their screening mammogram results after the exam or receive their test results within 48 hours, according to new research published in the Journal of the American College of Radiology.

Researchers led by Biren A. Shah, MD, a radiologist at the Virginia Commonwealth University Health System in Richmond, Virginia, also found from survey responses from 2,245 screening mammography patients 18 years and older that most (85.4 percent) preferred to receive abnormal screening mammogram results on a Friday—even if they couldn’t come in for a diagnostic workup until the following week. ”

(#100) AI detects breast cancer as well as most radiologists (Radiology Business March 6, 2019)

“Artificial intelligence (AI) systems can achieve a cancer detection accuracy similar to that of an average breast radiologist, according to new findings published by the Journal of the National Cancer Institute.

“Considering the increasing scarcity of radiologists in some countries, including breast screening radiologists, alternative strategies to allow continuation of current screening programs are required,” wrote Alejandro Rodriguez-Ruiz, MSc, Radboud University Medical Center in the Netherlands, and colleagues. “In addition, it is of paramount importance to prevent visible lesions in digital mammography (DM) being overlooked or misinterpreted.””

(#99) Imaging groups collaborate on ethics in AI draft document (Health Imaging March 4, 2019)

“A group of imaging societies, including the American College of Radiology (ACR) and Society for Imaging Informatics in Medicine (SIIM), came together to publish a draft document guiding a future of ethical AI.

The European Society of Radiology, RSNA, European Society of Medical Imaging Informatics, Canadian Association of Radiologists and American Association of Physicists in Medicine also worked on establishing the consensus document titled “Ethics of AI in Radiology: European and North American Multisociety Statement.””

(#98) AI Improves Grading Tumor Patterns and Subtypes of Lung Cancer (Genetic Engineering and Biotechnology News March 4, 2019)

“Currently, lung adenocarcinoma requires pathologist’s visual examination of lobectomy slides to determine the tumor patterns and subtypes. This classification has an important role in prognosis and determination of treatment for lung cancer, but it is a difficult and subjective task, according to Saeed Hassanpour, PhD, assistant professor of biomedical data science at Dartmouth Geisel School of Medicine.

Using recent advances in machine learning, the scientists, led by Hassanpour, developed a deep neural network to classify different types of lung adenocarcinoma on histopathology slides, and found that the model performed on par with three practicing pathologists.”

(#97) How did big policy changes impact cost sharing for screening mammography? (Radiology Business March 4, 2019)

“Nearly all commercially insured women between the ages of 40 and 74 had access to screening mammography without cost sharing after the Affordable Care Act (ACA) was signed into law, according to new research published by the Journal of the American College of Radiology. However, the authors noted, mammography utilization has dropped in recent years due to another significant policy shift.

When the ACA was signed in 2010, it required healthcare plans to eliminate cost sharing for preventive services such as mammography when the service received an “A” or “B” rating from the U.S. Preventive Services Health Task Force (USPSTF). The USPSTF, meanwhile, changed annual screening for women between the ages of 40 and 49 from a “B” rating to a “C” in 2009, leaving the costs associated with such screening in question.”

(#96) Imaging societies collaborate on draft document about ethics of AI in radiology (Radiology Business March 4, 2019)

“Several imaging societies, including the American College of Radiology (ACR) and European Society of Radiology, have published a consensus draft document focused on the ethics of AI in radiology.

RSNA, the Society for Imaging Informatics in Medicine, the European Society of Medical Imaging Informatics, the Canadian Association of Radiologists and the American Association of Physicists in Medicine all also contributed to the document, which is available to read on the ACR’s website.”

(#95) New biomedical gel could ease pain in cervical cancer treatment (Virginia Tech November 26, 2018)

“A unique partnership between a Virginia Tech scientist and a University of Virginia oncologist could result in a solution to reduce discomfort during cancer treatment for women.

Tim Long, a professor of chemistry with the Virginia Tech College of Science, and Tim Showalter, a radiation oncologist at UVA’s Cancer Center, are testing a gel that could be used during radiation treatment for cervical cancer.”

(#94) The future of voice recognition in healthcare — key thoughts from 8 CMIOs (Becker’s Healthcare November 27, 2018)

“Eight chief medical information officers discuss voice recognition technology and how it could impact the healthcare industry, from clinical documentation to decision support tools.”

(#93) 3 takeaways from a new survey of women undergoing mammography (Radiology Business March 1, 2019)

“A team of researchers surveyed more than 2,500 women before they underwent screening mammography, asking them about anxiety, how often they think about breast cancer and more. The authors, sharing their findings in the Journal of the American College of Radiology, noted the results could help influence shared decision-making related to breast cancer and breast cancer screening.

The researchers received responses from 2,747 women from five different breast imaging facilities. All surveys occurred between Sept. 1, 2016, and March 31, 2017. More than 51 percent of respondents had no major known breast cancer risk factors, and more than 78 percent had no personal history of breast cancer.”

(#92) How AI can help ‘see beyond’ breast density, provide more individualized patient care (Health Imaging February 27, 2019)

“Mammography is an essential screening and diagnostic tool for the detection of breast cancer and the assessment of breast density. But according to Victoria L. Mango, MD, a breast radiologist at Memorial Sloan Kettering Cancer Center in New York City, AI can help breast imagers and physicians see beyond basic breast density information provided by mammographic images and improve clinical management overall.

Although federal law now requires mammography facilities to include breast density information in reports for patients and their physicians, mammography screening recommendations are dependent on a women’s age and it can be difficult to determine which women with dense breasts will benefit the most from supplemental testing, according to Mango.”

(#91) New carotid imaging technique offers speedy, noninvasive CVD risk assessment (Cardiovascular Business February 12, 2019)

“A new, noninvasive technique for imaging the carotid artery can offer insight into plaque characteristics in real time, leading one researcher to suggest the modality could become as popular as ultrasound.

That researcher, Daniel Razansky, PhD, and co-authors published their early experience with volumetric multi-spectral optoacoustic tomography (vMSOT) on Feb. 12 in Radiology. The new technique involves holding a handheld device to a patient’s neck as spectroscopy provides images up to 30 mm deep, which is enough to visualize the carotid bifurcation area in most patients, Razansky and co-authors wrote. Many ischemic strokes are related to carotid artery disease originating from that area.”

(#90) Only 25% of radiologists are happy at work, survey finds (Health Imaging February 25, 2019)

“Radiologists are mildly happy at work compared to other physician specialties, according to Medscape’s 2019 Radiology Lifestyle, Happiness & Burnout Report, with only 25 percent claiming to be “very or extremely happy” in the workplace.

Medscape surveyed more than 15,000 physicians spanning 29 specialties for their annual report released in January. Their radiology-specific report was published Feb. 20, and in it, radiology ranked 20th among all specialties in terms of workplace happiness. Infectious disease specialists and anesthesiologist ranked alongside radiologists. Plastic surgeons and preventative health specialists were most happy at work, while internal medicine, emergency medicine and rehabilitation specialists rounded out the bottom.”

(#89) 4 areas AI must excel in to improve women’s imaging (Health Imaging February 21, 2019)

“For AI to become clinically feasible in women’s imaging, it must excel in the areas of performance, time, workflow and cost, according to an opinion piece published online Feb. 19 in the American Journal of Roentgenology.

The adoption of any new technology must achieve certain metrics to become viable and quantify its impact, wrote authors Ray C. Mayo, MD, and Jessica W. T. Leung, MD, each with the department of diagnostic radiology at The University of Texas MD Anderson Cancer Center in Houston.”

(#88) Machine learning model may save women from unnecessary breast surgery (Health Imaging February 26, 2019)

“Researchers have created a machine learning model that identified 98 percent of malignant atypical ductal hyperplasia (ADH) lesions prior to surgery, according to a single-center study published in JCO Clinical Cancer Informatics. The approach saved 16 percent of women from unnecessary surgery.

Lead researcher Saeed Hassanpour, PhD, of Dartmouth University in Hanover, New Hampshire and colleagues analyzed 128 lesions from 124 women with core needle biopsy-confirmed ADH who also underwent surgery.”

(#87) Can radiologists who interpret mammograms make the switch to DBT? (Health Imaging February 26, 2019)

“Radiologists who interpret traditional two-dimensional (2D) mammograms required little time in transitioning to reading digital breast tomosynthesis (DBT) exams, or three-dimensional (3D) mammograms, and improved their accuracy in detecting cancer, according to research published online Feb. 26 in Radiology.

The study, led by Diana Miglioretti, PhD, dean’s professor of biostatistics at the University of California Davis Department of Public Health Services, found these radiologists also recalled patients for additional testing at a lower rate on DBT than 2D mammography regardless of whether patients did or did not have dense breasts. ”

(#86) Breast cancer prediction models more effective when they include family history data (Radiology Business February 26, 2019)

“Breast cancer prediction models based on family history are more effective than those that do not focus on that information, according to a new study published in The Lancet Oncology.

The authors studied data on more than 15,000 women from Australia, Canada and the United States who belonged to the Breast Cancer Prospective Family Study Cohort. All women analyzed for the study were between the ages of 20 and 70, did not have breast cancer when they were recruited into the cohort and had an available family history of breast cancer.”

(#85) Ultrasound assesses bone health similarly to DXA, study finds (Health Imaging February 26, 2019)

“Ultrasound scans of the calcaneus—or the heel bone—were equal to results gathered from dual-energy x-ray absorptiometry (DXA) for assessing bone health, according to new research published online in the March issue of The Journal of the American Osteopathic Association.

The study suggests that ultrasound could be offered as a low-cost, more accessible method of screening for osteoporosis and other bone diseases, wrote researchers led by Carolyn Komar, PhD, associate professor of biomedical sciences at the West Virginia School of Osteopathic Medicine in Lewisburg.”

(#84) How AI can improve mammography (AI in Healthcare February 21, 2019)

“There are four areas in which AI must excel to become clinically viable in women’s medical imaging—particularly mammography: performance, time, workflow and cost, according to an opinion article published in the American Journal of Roentgenology.

“AI holds tremendous potential for transforming the practice of radiology, but certain metrics are needed to objectively quantify its impact,” wrote authors Ray C. Mayo, MD, and Jessica W.T. Leung, MD, of the University of Texas MD Anderson Cancer Center in Houston. “As patients, physicians, hospitals and insurance companies look for value, AI must earn a role in medical imaging.”

(#83) New carotid imaging technique offers speedy, noninvasive CVD risk assessment (Cardiovascular Business February 12, 2019)

“A new, noninvasive technique for imaging the carotid artery can offer insight into plaque characteristics in real time, leading one researcher to suggest the modality could become as popular as ultrasound.

That researcher, Daniel Razansky, PhD, and co-authors published their early experience with volumetric multi-spectral optoacoustic tomography (vMSOT) on Feb. 12 in Radiology. The new technique involves holding a handheld device to a patient’s neck as spectroscopy provides images up to 30 mm deep, which is enough to visualize the carotid bifurcation area in most patients, Razansky and co-authors wrote. Many ischemic strokes are related to carotid artery disease originating from that area.”

(#82) New guidelines recommend genetic testing for all breast cancer patients (Radiology Business February 15, 2019)

“Genetic testing should be available for all breast cancer patients to determine hereditary risk in addition to standard imaging exams, according to new guidelines published Feb. 14 by The American Society of Breast Surgeons.

The new recommendations are based on an extensive review of supporting research, especially a study published in the Journal of Clinical Oncology in December which found that patients who met existing National Comprehensive Cancer Network (NCCN) clinical testing criteria had similar rates of genetic mutations in breast cancer genes as patients who did not meet the criteria.”

(#81) New federal law requires mammography providers to send breast density notifications (Radiology Business February 19, 2019)

“When President Donald Trump signed a federal funding bill into law on Feb. 15, it included text that said that all mammography providers must include updated information about breast density in reports sent to both patients and their physicians.

The notifications sent out to patients will inform them about their own personal breast density and explain the importance of that information. More than 30 states currently require such information to be shared with patients after they undergo a mammogram, a number that has been rising steadily for years.”

(#80) Hails Federal Law that Mandates that Mammography Reports Include Breast Density Information (Cision February 19, 2019)

“DEER PARK, N.Y., Feb. 19, 2019 /PRNewswire/ — National breast density inform legislation was enacted as part of the funding bill signed into law on February 15.  The Federal legislation will require mammography facilities to include up-to-date information about breast density in mammography reports provided to patients and their physicians.  This follows 36 state laws that require communication about breast density to women after their mammogram, according to

As announced by Senator Dianne Feinstein (CA) on February 16, “As part of the funding bill Congress passed yesterday, the FDA must now ensure mammography reports include appropriate breast-density information. Dense tissue can hide cancer on mammograms, so this information is vital to catching breast cancer early.””

(#79) Researchers call for a closer look at speech recognition in radiology and beyond (Radiology Business February 13, 2019)

“Speech recognition has become a staple software category in radiology over the past three decades, and other medical specialties have adopted it as well. Yet efforts to assess the toolset’s applications and adaptations have been frustrated by the lack of a unified set of metrics.

Thanks to the resulting jumble, the time is ripe to put speech recognition under a focused research microscope for a full examination.

So suggest the authors of a study published online in the Journal of the American Medical Informatics Association.”

(#78) Surveillance imaging after MRI-guided breast biopsy varies by institution, radiologist (Health Imaging February 13, 2019)

“Imaging follow-up protocols vary greatly by institution and radiologist after benign, concordant MRI-guided percutaneous core needle biopsies (MR-PCNB), according to research published online Feb. 7 in the Journal of the American College of Radiology.

Because no consensus guidelines for imaging follow-up protocols after benign concordant MR-PCNB exist, conflicting data and unclear management guidelines can lead to variability in radiology practices and uncertainty among breast radiologists and their patients, wrote lead author Bhavika K. Patel, MD, of the Mayo Clinic in Phoenix, and colleagues. “

(#77) How common are complications during stereotactic vacuum-assisted breast biopsies? (Radiology Business February 11, 2019)

“Significant complications are rarely associated with stereotactic vacuum-assisted breast biopsies (SVABs), according to new research published in the American Journal of Roentgenology.

The study’s authors wrote that unnecessary biopsies and complications related to biopsies are often cited as potential harms of mammographic breast cancer screening, and the U.S. Preventive Services Task Force (USPSTF) specifically used such issues to help explain why it changed its mammography recommendations in 2009. Noting that there has not been much recent research on this specific topic, the team wanted to explore how often such complications occur.”

(#76) PET technique may allow for earlier measurement of breast cancer therapy effectiveness (Health Imaging February 11, 2019)

“A molecular imaging technique using PET technology may improve how the efficacy or failure of hormone therapy is measured for breast cancer patients, according to research published online in the February issue of The Journal of Nuclear Medicine.

Researchers from the University of Wisconsin School of Medicine and Public Health in Madison, Wisconsin, found that positron emission tomography (PET) imaging with 18F-fluorofuranylnorprogesterone (18F-FFNP) can successfully measure changes in progesterone receptor (PR) levels which results from a short-course estrogen treatment, also known as an estradiol challenge.”

(#75) Mobile breast cancer screening unit to tour UAE (Radiology Business February 11, 2019)

“A mobile breast cancer screening unit will soon tour the United Arab Emirates to offer free consultations, mammography screenings and genetic testing for men and women.

According to a recent report from the English-language daily news outlet The National, The Pink Caravan, established in 2011, will have 30 buses filled with nurses and clinicians traveling between February 21 and March 2 to promote early breast cancer diagnosis. A fixed clinic will also be providing services in Abu Dhabi during that time.”

(#74) HL7 Receives Letter of Support from CMS (February 5, 2019)

“Dear Dr. Jaffee:

Thank you for collaborating in accelerating standards. Recognizing the importance of your work in moving forward to a truly collaborative, interoperable health system that supports patients in seeking low cost, high quality care, the Centers for Medicare & Medicaid Services (CMS) is excited to contribute our priorities for the upcoming year. Top of mind for CMS is ensuring the seamless flow of data, not only from provider to provider, but also including payers, beneficiaries and the opportunity to facilitate innovation by unleashing data for use by researchers, application developers and others. The CMS priorities that will continue to be highlighted in our work this year are:”

(#73) 14-layer CNN accurately predicts breast cancer molecular subtype (Health Imaging February 4, 2019)

“A 14-layer convolutional neural network (CNN) trained on MRI and pathology data accurately predicted the molecular subtype of breast cancers, according to a Jan. 31 study published in the Journal of Digital Imaging. The method may help personalize treatment plans for the disease.

Trained on available breast MRIs and immunohistochemical (IHC) staining pathology data of 216 patients with known breast cancer, the CNN predicted breast cancer subtype with 70 percent accuracy. A balanced holdout set of 40 patients was used as the testing set.”

(#72) New small cell lung cancer model reveals critical role of two mutated genes (Fierce BioTech February 11, 2019)

“Small cell lung cancer (SCLC) develops mostly in smokers and is so aggressive it almost always becomes resistant to chemotherapy and radiation. The disease is widely believed to originate from pulmonary neuroendocrine cells (PNECs), but they have proven difficult to generate in the lab, making it challenging for oncology researchers to study SCLC and find new therapies.

Researchers from Weill Cornell Medicine in New York have figured out how to grow PNECs from human embryonic stem cells—and in so doing they’ve gained new insight into two genes that are commonly mutated in SCLC. They believe their new model of the disease will be useful for fine-tuning treatments at various stages of tumor development.”

(#71) MacroGenics Stock Soars on Positive Breast Cancer Trial Results (The Street February 6, 2019)

“MacroGenics (MGNX) shares soared on positive results from Sophia, its late-stage clinical study of the efficacy of margetuximab in patents with HER2-positive metastatic breast cancer.

Shares rose 130.4% to $25.60 by the close of trading on Wednesday.

SVB Leerink analyst Jonathan Chang wrote in a note that “little value for the drug in the indication was represented in the stock going into the results,” according to Bloomberg. Nomura sees the stock between $19 and $28 on positive Sophia results, Bloomberg says. Nomera and Leerink played lead roles in MacroGenics’ public offering of 4,500,000 common shares priced at $21.25 in March 2018.”

(#70) Are radiology reports too difficult for patients to understand? (Health Imaging January 18, 2019)

“Although online portals allow some patients to easily access their radiology reports, a recent study published online Jan. 8 in the American Journal of Roentgenology found that lumbar spine MRI reports in particular are written at a reading level too advanced for the average patient to comprehend.

The National Institutes of Health and the American Medical Association recommend all patient education materials and reports be written at or below a six-grade reading level because the average U.S. adult reads at an eighth-grade level.”

(#69) Researchers developed an intelligent system for lung cancer diagnostics (Polytech February 4, 2019)

“Researches from Peter the Great St.Petersburg Polytechnic University (SPbPU), Russian Academic Excellence Initiative participant, in collaboration with the radiologists from St.Petersburg Clinical Research for Specialized Types of Medical Care (Oncological) have developed an intelligent software system for lung cancer diagnostics. This software can be installed on any computer. It analyzes patients’ computed tomography (CT) results within 20 seconds and provides an image in which the pathology is clearly marked. Reserachers have named the system Doctor AIzimov (AI for Artificial Intelligence) in honor of the science-fiction writer Isaac Asimov, who developed three famous laws of robotics.”

(#68) Researchers of SPbPU developed a unique equipment for ultrasound examination (Ultrasound mobile) (Polytech May 28, 2018)

“Researchers of the laboratory “Medical ultrasound equipment” of Peter the Great St. Petersburg Polytechnic University (SPbPU) developed a high-tech device-transformer for ultrasound examination, named “Ultrasound mobile”. The new equipment is the combination of three modifications in one device.

Currently, each modification functions separately in the medical centers, the scientists of St. Petersburg Polytechnic University became the first who combined it into a single hardware complex. Thus instead of two types of vehicles (stationary and portable), medical institutions can use single equipment for different purposes and in different wards.”

(#67) Providers need consensus guidelines for follow-up imaging after benign MRI-guided breast biopsies (Radiology Business February 8, 2019)

“More consistent follow-up protocols after benign concordant MRI-guided percutaneous core needle biopsies (MR-PCNBs) could lead to better overall patient care, according to a case study published in the Journal of the American College of Radiology.

“If radiologic-pathologic correlation is concordant with benign pathology, then patients may be recommended for imaging follow-up to confirm stability of imaging findings and to aid in early diagnosis of potentially false-negative results,” wrote Bhavika K. Patel, MD, Mayo Clinic in Phoenix, Arizona, and colleagues. “Studies have reported up to a 4 percent false-negative MR biopsy rate.””

(#66) Targeting the Immune System Keeps Skin Cancer From Returning (Laboratory Equipment February 8, 2019)

“People who have had one melanoma are much likelier to develop future skin cancers.

Researchers from Queen Mary University of London have discovered why—and found a potential therapeutic target to keep this aggressive cancer from coming back.

Melanomas are considered the most dangerous form of skin cancer by experts. When caught early, it is almost always curable. However, it can be difficult to treat once it has spread to other parts of the body.

Approximately 178,560 cases of melanoma were diagnosed in the United States in 2018.”

(#65) FDA updates providers on rare cancer associated with breast implants (Radiology Business February 7, 2019)

“The FDA has published a new letter to providers in radiology, pathology, emergency medicine and several other specialties with updated information related to breast implant associated-anaplastic large cell lymphoma (BIA-ALCL).

Patients are at “an increased risk” of developing BIA-ALCL “within the scar capsule adjacent to the implant,” according to the document, which is signed by William Maisel, MD, MPH, CMO of the FDA’s Center for Devices and Radiological Health.”

(#64) Interacting with primary care physicians improves screening mammography adherence (Radiology Business February 7, 2019)

“When primary care physicians (PCP) interact with their patients at a high level, it leads to improvements in breast cancer screening adherence for all racial and ethnic minority groups, according to new findings published in the Journal of the American College of Radiology.

“As the United States continues to become increasingly diverse, understanding factors that affect access to routine screening mammography is an important step in improving breast cancer disparities among racial/ethnic minority groups,” wrote Efrén J. Flores, MD, department of radiology at Massachusetts General Hospital in Boston, and colleagues.”

(#63) Electronic Bandage Can Speed Wound Healing (Design News February 5, 2019)

“Engineers at the University of Wisconsin (UW)–Madison developed a wound dressing, which uses the energy it harvests to send gentle electrical pulses to an injury site, treatment that helps significantly speed healing, they said in a UW news release.

Indeed, in tests on rodents, the so-called “e-bandage” reduced healing of wounds to three days instead of the usual two weeks it takes for them to completely heal, said Xudong Wang, a professor of materials science and engineering at UW–Madison who led the research.”

(#62) AI diagnoses lung cancers in 20 seconds (AI in Healthcare February 4, 2019)

“Russian researchers from the Peter the Great St. Petersburg Polytechnic University (SPbPU) and radiologists from St. Petersburg Clinical Research for Specialized Types of Medical Care developed AI software that can distinguish and subsequently mark lung cancers on a CT scan within 20 seconds.

The AI software, dubbed Doctor AI-zimov, can detect lung nodules as small as 2 millimeters on CT scans, according to a prepared statement issued by SPbPU.”

(#61) The Future of Radiology Reporting (Carestream February 5, 2019)

“Interactive, multi-media reporting is readily available within radiology workstations today – yet the majority of diagnostic imaging reports in the UK remain text based. In fact, the format of medical imaging reports created by most radiology departments has not changed much in over 100 years.

But this status quo is about to change. In the short and long term, reporting will undergo a considerable transformation.”

(#60) Why health systems must embrace the forthcoming CDS mandate (Health Imaging January 29, 2019)

“Upcoming legislation mandating the use of a clinical decision support (CDS) system when ordering advanced imaging tests could affect up to six million emergency department visits annually, according to estimates published in a Jan. 29 Radiology study. The law is set to go into effect in January 2020.

Congress passed The Protecting Access to Medicare Act (PAMA) in 2014, which put forth rules for CMS to establish the Appropriate Use Program for CDS systems that will be implemented in U.S. health systems serving Medicare beneficiaries. Providers who do not consult with a compliant CDS system will not be reimbursed for advanced imaging studies, according to the legislation.”

(#59) Bundled payment model for breast cancer screening is realistic, study finds (Health Imaging January 23, 2019)

“Previously established frameworks for creating breast cancer screening bundled payment models are achievable, according to a new study published in the Journal of the American College of Radiology. The approaches could also incorporate the rise of digital breast tomosynthesis (DBT).

In the study, researchers set out to evaluate the feasibility of a mammography bundled payment model and how a model for breast cancer screening created prior to widespread DBT adoption would fare after institutions have embraced the breast cancer screening method.”

(#58) OncoCyte blood test to rule out lung malignancies heads for commercial launch following study (Fierce Biotech January 29, 2019)

“OncoCyte has delivered new positive results from a study of its DetermaVu blood test for lung cancer, which is designed to rule out patients who have a suspicious lung nodule but do not require an immediate biopsy.

The test showed 90% sensitivity in spotting malignant nodules in a prospective study and 75% specificity in identifying those that were benign out of a cohort of 250 patient samples. In addition, the test made its determinations without including any clinical factors in its algorithm, such as the size of the lung nodule, the company said.”

(#57) Study: 25% of adults worldwide will have a stroke (Cardiovascular Business January 4, 2019)

“About one-quarter of adults in the world will experience a stroke in their lifetime, according to new estimates from the Global Burden of Disease Study (GBDS) published online Dec. 20 in the New England Journal of Medicine.

The GBDS 2016 used all available epidemiologic data to assess health loss from 328 diseases across 195 countries and territories from 1990 through 2016. With this information, corresponding author Gregory A. Roth, MD, and colleagues sought to calculate the cumulative lifetime incidence of a first stroke—including ischemic or hemorrhagic strokes—among adults 25 or older.”

(#56) DBT associated with lower recall rate, makes no impact on cancer detection rate (Radiology Business January 28, 2019)

“The implementation of digital breast tomosynthesis (DBT) at eight radiology facilities in Vermont led to lower recall rates than full-field digital mammography (FFDM) alone, according to a new study published in the American Journal of Roentgenology. However, the authors observed no improvements in cancer detection rates.

The authors explored data from the Vermont Breast Cancer Surveillance system, including more than 97,000 FFDM examinations and more than 86,000 DBT examinations from 2012 through 2016.”

(#55) Black women wait longer for breast surgery than white women, study finds (Health Imaging January 25, 2019)

“New research involving breast cancer patients in the U.S. Military Health System found that black women wait longer to undergo breast cancer surgery after being diagnosed with the disease than white women, according to a study published Jan. 23 in JAMA Surgery.

Researchers led by Kangmin Zhu, MD, PhD, of the John P. Murtha Cancer Center at the Uniformed Services University of the Health Sciences in Rockville, Maryland, noted that the longer time to surgery, however, did not account for the observed racial disparity in overall survival.”

(#54) Bayer gets with the program for Super Bowl LIII to kick off cancer testing awareness effort (Fierce Pharma January 29, 2019)

“Bayer is going to the Super Bowl. Not with some glitzy $5 million TV ad, but instead with a print ad in the official Super Bowl LIII program to launch its new awareness campaign around genomic testing for cancer.

The “Test Your Cancer” campaign soft launch begins with the Super Bowl ad along with focused digital ad buys in an effort to make people aware of genomic testing options for solid tumor cancer patients.”

(#53) How radiologists can eliminate these 4 lung cancer screening barriers (Health Imaging January 9, 2019)

“A new article published in Radiology explores the barriers patients face in undergoing lung cancer screening (LCS), and more importantly, what radiologists can do to encourage their participation.

“Radiologists are essential to every LCS program,” wrote Gary X. Wang, of Massachusetts General Hospital in Boston, and colleagues. “Increased awareness of challenges faced by patients and referring providers will empower radiologists to continue to collaboratively guide nationwide multidisciplinary efforts to implement LCS.””

(#52) Noninvasive Test for Colon Cancer Screening Offered as an Alternative to Colonoscopy for Screening (Medical Device and Diagnostic Industry January 8, 2019)

““The only real cure for cancer is finding it early,” said Padma Sundar, vice president of strategy and market access at CellMax Life, in an interview with MD+DI. In terms of colorectal cancer, she said it takes a long time for an adenoma to develop into cancer, so early detection of these adenomas can be lifesaving.”

(#51) Long-Term Study of 1,000 Tumors Demonstrates Effectiveness of iCAD’s Xoft Electronic Brachytherapy System for Early-Stage Breast Cancer Treatment (Globe News Wire January 7, 2019)

“iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the results of a long-term study conducted at Hoag Memorial Hospital Presbyterian with the Xoft® Axxent® Electronic Brachytherapy (eBx®) System® for the treatment of early-stage breast cancer using intraoperative radiation therapy (IORT).”

(#50) Machine learning approach requires less data to identify follow-up guidance in radiology reports (Health Imaging January 3, 2019)

“Follow-up recommendations in radiology reports commonly contain little standardization. Machine learning and deep learning (DL) methods are each effective for deciphering reports and may provide the foundation for real-time recommendation extraction, according to a recent study in the Journal of the American College of Radiology.

“Radiology reports with follow-up recommendations are difficult to identify, in part because of their free-text nature and their lack of standardized structure and content,” wrote first author Emmanuel Carrodeguas, MD, of Harvard Medical School in Boston, and colleagues…””

(#49) New Role Found for Protein in Preventing Breast Cancer Growth and Spread (Genetic Engineering and Biotechnology News January 14, 2019)

“Scientists at the LSU Health New Orleans School of Medicine have found a new role for a protein in preventing the growth and spread of breast cancer. The results of the study (“Exosomes from Nischarin-Expressing Cells Reduce Breast Cancer Cell Motility and Tumor Growth”), which researchers believe could have a significant impact on cancer therapy, were published in the OnlineFirst section of Cancer Research…”

(#48) Preventing breast cancer metastasis by killing tumor cells in their sleep (Fierce Biotech January 21, 2019)

“Oncology researchers have long believed that “dormant” breast cancer cells—those that have stopped dividing and are merely hiding out in the body—are unresponsive to chemotherapy. Yet those inactive cancer cells can wake up at any time and cause life-threatening metastases.

Scientists at the Fred Hutchinson Cancer Research Center say they’ve figured out how to prevent dormant breast cancer cells from ever waking up, and that the key is to disrupt a signaling system in blood vessels that protects the cells as they sleep…”

(#47) Optical imaging system visualizes molecular features of breast cancer tissue in real-time (Health Imaging December 20, 2018

“A team of researchers from the University of Illinois at Urbana-Champaign has developed a portable optical imaging system that can visualize molecular features of breast tissue after it’s been surgically removed from a patient, according to research published online Dec. 19 in Science Advances.

Able to track tumor progression, the tool may provide cancer researchers more in-depth information regarding cancer tissue pathology and diagnostics in real-time…”

(#46) Breast-specific gamma imaging could help predict pathologic response to chemotherapy (Health Imaging January 11, 2018)

“Breast-specific gamma imaging (BSGI) performed with comparable sensitives in detecting residual tumor compared to breast MRI, and may be a more useful tool for predicting a complete pathologic response to neoadjuvant chemotherapy (NAC) in those with breast cancer, according to research published online Jan. 8 in the American Journal of Roentgenology.

BGSI is a relatively new nuclear medicine imaging tool that can be used as a complementary modality for initial breast cancer diagnosis, according to Shannon Kim, MD, radiologist at Eastern Virginia Medical School, and colleagues. The authors noted, however, that few studies have compared the accuracy of BSGI and breast MRI for such clinical situations…”

(#45) According to the National Cancer Institute’s Surveillance, Epidemiology, and End Results Program

Breast cancer represented 15.3% of all new cancer cases and 6.7% of all cancer deaths in 2018. There were an estimated 266,120 new cases of breast cancer in the U.S. and an estimated 40,920 deaths.

(#44) Novel Technique May Significantly Reduce Breast Biopsies (Imaging Technology News January 17, 2019)

“A novel technique that uses mammography to determine the biological tissue composition of a tumor could help reduce unnecessary breast biopsies, according to a new study appearing in the journal Radiology.1

Mammography has been effective at reducing deaths from breast cancer by detecting cancers in their earliest, most treatable stages. However, many women are called back for additional diagnostic imaging and, in many cases, biopsies, for abnormal findings that are ultimately proven benign. Research estimates this recall rate to be more than 10 percent in the United States.”

(#43) The 10 Pillars of Lung Cancer Screening: Rationale and Logistics of a Lung Cancer Screening Program (RSNA October 23, 2015)

“Lung cancer accounts for more deaths than any other cancer in both men and women and caused an estimated 436 deaths per day in the United States in 2014 (1). When diagnosed after symptoms occur, lung cancer is typically advanced, resulting in a dismal 5-year survival rate of 17.4% (2). Although lung cancer is one of the top four deadliest cancers and is curable when detected at an early stage, routine screening for lung cancer has not been performed until recently. Although multiple randomized trials had been conducted, no screening test had been shown to reduce lung cancer–specific mortality until the June 2011 release of data from the landmark National Lung Cancer Screening Trial (NLST) (Fig 1) (3,4).”

(#42) Bundled payment model for breast cancer screening is realistic, study finds (Health Imaging January 23, 2019)

“Previously established frameworks for creating breast cancer screening bundled payment models are achievable, according to a new study published in the Journal of the American College of Radiology. The approaches could also incorporate the rise of digital breast tomosynthesis (DBT).

In the study, researchers set out to evaluate the feasibility of a mammography bundled payment model and how a model for breast cancer screening created prior to widespread DBT adoption would fare after institutions have embraced the breast cancer screening method.”

(#41) DBT associated with more accurate biopsy recommendations (Radiology Business January 23, 2019)

“Digital breast tomosynthesis (DBT) implementation in a diagnostic setting can result in an improved cancer detection rate (CDR) and more accurate biopsy recommendations, according to a new case study published in the Journal of the American College of Radiology.

“Although DBT may better characterize malignant and benign features, and therefore have the potential to decrease unnecessary imaging follow-up and ultimately benign biopsies, the current literature is inconsistent,” wrote Emily B. Ambinder, MD, of Johns Hopkins Medical Institutions in Baltimore, Maryland, and colleagues. “Therefore, we aimed to add to this important topic by assessing the impact of DBT on outcomes in the diagnostic setting.””

(#40) How a radiology department improved its national ranking in patient experience (Radiology Business January 23, 2019)

“Considering the continued focus on quality over quantity and the rise of online reviews, patient experience has never been more important in healthcare than it is today. A new study published by Radiology tracked one radiology department’s efforts to assess its own patient experience, identify improvement opportunities and make a difference.

“Studies in several radiology departments have cited various factors as important to patients including wait times, acknowledgment of concerns, friendliness of support staff, convenience of parking, and comfort of the waiting area,” wrote Neena Kapoor, MD, department of radiology at Brigham and Women’s Hospital in Boston, and colleagues. “However, it is unknown whether these factors are amenable to change or whether improving these factors can measurably improve patient experience.””

(#39) Vancouver risk calculator found to improve lung cancer screening (Health Imaging January 22, 2019)

“The Vancouver risk calculator (VRC) offers superior guidance in predicting the risk of malignancy in patients receiving CT lung cancer screening compared to the American College of Radiology Lung Imaging Reporting and Data System (Lung-RADS), according to a new study.

Authors of the research, published Jan. 22 in Radiology, did report the Vancouver method was less specific and less accurate when it came to subsolid nodules.

In the study, researchers scored more than 4,400 nodules taken from 2,813 patients as part of the National Lung Screening Trial (NLST). The nodules were scored using VRC with nine parameters and Lung-RADS. Of the total, 4,078 nodules were solid, 330 were subsolid.”

(#38) 23andMe Receives FDA Clearance for Direct-to-Consumer Genetic Test on a Hereditary Colorectal Cancer Syndrome (MorningStar January 22, 2019)

“23andMe, Inc., the leading personal genetics company, today received FDA clearance for a genetic health risk report on a hereditary colorectal cancer syndrome.

The clearance follows the FDA’s authorization for 23andMe’s BRCA1/BRCA2 (Selected Variants) Genetic Health Risk report in March 2018. The MUTYH-Associated Polyposis report was submitted to the FDA using the 510(k) submission pathway, enabled by the BRCA decision in March 2018. These two reports are the only direct-to-consumer genetic health risk reports for inherited cancers that have been authorized or cleared by the FDA for use without prescription.”

(#37) Providers begin using AI to improve clinical decision making (Health Data Management January 22, 2019)

“Healthcare organizations across the country are beginning to cash in on early efforts in artificial intelligence and data visualization.

First reports on initial efforts to use these advanced technologies show tantalizing potential.

At Massachusetts General Hospital researchers have developed an AI algorithm to rapidly diagnose and classify brain hemorrhages from unenhanced computed tomography scans, detecting acute incidents and offering prediction capabilities that eventually could help staff in hospital emergency departments evaluate patients with acute stroke symptoms.”

(#36) Alphabet CFO: Our AI is so good we can detect breast cancer with less data than ever (CNBC January 22, 2019)

“Major breakthroughs are now possible with less data than ever thanks to artificial intelligence, Alphabet Chief Financial Officer Ruth Porat said during a panel at the World Economic Forum in Davos, Switzerland Tuesday.

Artificial intelligence “learns” patterns by ingesting typically large amounts of data and then using that information to complete a task, like sorting data into different buckets. Porat said less data is required than before to see impactful results from AI, citing a recent example of medical breakthrough aided by Alphabet technology.”

(#35) Predicting Lung Cancer Earlier Using Genomics (Genetic Engineering & Biotechnology News January 22, 2019)

“Novel methods for early detection are critical for improving cancer treatments and outcomes. This is especially true for lung cancer, the most common cause of cancer death worldwide, with over 1.5 million deaths per year. Now, the world’s first genetic sequencing of precancerous lung lesions has allowed researchers for the first time, to discover the differences between the lesions that will become invasive and those that are harmless, and the subsequent development of a method that can accurately predict which lesions will become cancerous.

The work, published on January 21st in Nature Medicine, titled “Deciphering the genomic, epigenomic, and transcriptomic landscapes of preinvasive lung cancer lesions” may pave the way for very early detection and new treatments.”

(#34) Breast MRI may help personalize treatment for DCIS patients (Health Imaging January 21, 2019)

“Pairing breast MRI with a test that characterizes breast cancer genes can lead to a more personalized treatment approach for patients with ductal carcinoma in situ (DCIS), reported authors of a recent study published in JAMA Oncology.

The study, which included 75 institutions, enrolled 339 women with DCIS on core biopsy who were also eligible for wide local excision (WLE) surgery. Patients received breast MRI before surgery and those results were considered when determining surgical choice. A test called the 12-gene DCIS score assay—a 10-year risk recurrence test on a scale of 0 to 100—guided radiotherapy recommendations.”

(#33) DBT helps reduce recall rates, commit fewer patients to short-term follow-up (Radiology Business January 21, 2019)

“Implementing digital breast tomosynthesis (DBT) can lead to fewer women being committed to short-term follow-up, according to new research published in Academic Radiology.

The authors explored BI-RADS classifications from a single institution that first made DBT available in September 2011. More than 11,000 breast cancer screening examinations with digital mammography (DM) from before implementation (Sept. 1, 2010 to August 31, 2011) were compared with more than 9,000 examinations with DBT and DM after implementation (Jan. 1, 2014 to June 30, 2015). All examinations were read by one of a team of five radiologists.”

(#32) College of American Pathologists release digital pathology guidelines for testing breast cancer (Health Imaging January 18, 2019)

“The College of American Pathologists released 11 new evidence-based clinical recommendations to help labs better use quantitative image analysis (QIA) in HER2 testing for breast cancer.

The first-ever guidelines put forth steps to validate QIA before implementing along with maintenance steps to assure quality and control while testing. The college recommends labs validate QIA results by comparing them to an alternative, validated method such as HER2 in-situ hybridization protocol or consensus images.”

(#31) Plaque characteristics boost predictive power of CTA risk scoring (Cardiovascular Business January 18, 2019)

“A CT angiography (CTA)-derived score that also incorporated the extent, location and composition of coronary plaque outperformed a model that focused only on the severity of stenosis, researchers reported Jan. 16 in JACC: Cardiovascular Imaging.

Coronary CTA reading is currently guided by the Coronary Artery Disease-Reporting and Data system (CAD-RADS), and that assessment is predicated mostly on the maximal degree of stenosis observed. However, lead author Alexander R. van Rosendael, MD, and colleagues noted that other coronary plaque characteristics including its location (proximal versus distal), composition (calcified, noncalcified or mixed) and the number of plaques have been linked to clinical outcomes in previous studies.”

(#30) DBT outperforms FFDM when screening patients with dense breast tissue (Radiology Business January 18, 2019)

“Invasive lobular, low-grade and HER-2-negative breast cancers are more detectable with digital breast tomosynthesis (DBT) than conventional full-field digital mammography (FFDM) when imaging patients with dense breasts, according to a new study published in the Korean Journal of Radiology.

The authors asked three blinded radiologists to review DBT and FFDM images from 288 patients with dense breasts with a mean age of 48.5 years. They reviewed the images during two separate review sessions held at least one month apart, making notes where they detected tumors. Two non-blinded radiologists then reviewed DBT and FFDM images as well as ultrasound and MR images. The non-blinded radiologists scored the work of each individual blinded radiologist to determine a “detectability score” for all of the malignancies.”

(#29) Stationary DBT improves reader accuracy compared to mammography (Radiology Business January 17, 2019)

“Stationary digital breast tomosynthesis (sDBT), which allows views to be collected without  moving the x-ray tube, leads to improved reader accuracy compared to mammography, according to new findings published in Academic Radiology.

“In 2016, about one-third of all screening evaluations included DBT, at which time a standard mammogram was also obtained in most cases,” wrote Yueh Z. Lee, MD, PhD, of the department of radiology at the University of North Carolina at Chapel Hill, and colleagues. “However, since combined imaging doubles the radiation dose and increases cost, work continues to improve DBT, with a goal of eliminating the need to collect a standard mammogram at the same time.””

(#28) USPSTF recommends offering medication to women at increased risk for breast cancer (Radiology Business January 16, 2019)

“The U.S. Preventive Services Task Force (USPSTF) has published a draft recommendation statement and draft evidence review that says clinicians should offer “risk-reducing medications” to women at an increased risk for breast cancer. Those women should also be at a low-risk for any adverse effects associated with such medication, the USPSTF added.

This represents a “B” recommendation from the independent group. Offering women not at an increased risk for breast cancer risk-reducing medications gets a “D” recommendation, meaning it is not recommended.”

(#27) 3 ways to demonstrate the true value provided by radiologists (Radiology Business January 14, 2019)

“Radiologists provide significant value. According to a new analysis published in the Journal of the American College of Radiology, however, the specialty is still judged by “checkbox metrics” that do not illustrate its true value.

Measuring value in healthcare is difficult, primarily because current payment programs are based on specific clinical processes. It’s even more challenging in radiology because it can be hard to connect a radiologist’s efforts to a patient outcome. So, what can be done to improve the daily discussion that revolves around value?”

(#26) Increased spending on chronic conditions such as breast cancer a smart investment (Radiology Business January 14, 2019)

“Spending on treating chronic conditions has skyrocketed in the United States, but it is an investment that has paid off for patients.

Researchers explored healthcare spending from 1996 to 2015, sharing their findings in Health Affairs. The team focused on spending associated with breast cancer, lung cancer, cerebrovascular disease, chronic obstructive pulmonary disease (COPD), diabetes, HIV/AIDS and ischemic heart disease. In 1996, for example, more than $1.9 billion was spent on treating breast cancer. That number jumped to more than $12.5 billion in 2015. Significant increases were found in all seven conditions, leading the researchers to wonder if more spending has led to better patient outcomes.”

(#25) SBI publishes policy statement on diversity, inclusion (Radiology Business January 11, 2019)

“The Society of Breast Imaging (SBI) has issued a new policy statement on diversity and inclusion, emphasizing the belief that “all people for whom breast cancer screening is appropriate should receive the opportunity to undergo screening.”

The statement, produced by the SBI Communications and Advocacy Task Force, begins by noting that the most effective way to minimize the impact of breast cancer is for all women at an average risk to get annual screening mammograms beginning at the age of 40 and “continue as long as they are in good health.””

(#24) How a breast imaging center plans to improve patient-centered care (Health Imaging January 3, 2019)

“Long wait times can negatively impact patient satisfaction, which then harms the patient-centered, value-based care imaging departments seek to provide. But collecting the necessary data for improvements can be difficult, according to the authors of a case study published in the Journal of Digital Imaging. At one large hospital-based outpatient breast imaging department, researchers implemented a real-time location system (RTLS) to pinpoint problems areas experienced when performing full field digital mammograms (FFDM) and digital breast tomosynthesis (DBT) exams.”

(#23) Veracyte Finds Ally in J&J for Early Lung Cancer Detection (MD+DI January 3, 2019)

“A new collaboration between Johnson & Johnson Innovation and Veracyte, a genomic diagnostics company, will focus on the detection of lung cancer. The long-term agreement will be used to advance the development and commercialization of novel diagnostic tests to detect lung cancer at its earliest stages, when the disease is most treatable.”

Start typing and press Enter to search